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Abstract 
Streptococcus pneumoniae (S. pneumoniae) is a Gram-positive, encapsulated 
bacterium capable of causing significant morbidity and mortality throughout the world. A 
hallmark of S. pneumoniae infection is infiltration of neutrophils (PMNs) that assist in 
controlling the spread infection but may also contribute to pathology. Paradoxically, 
studies have shown that limiting PMN infiltration into the lumen of the lung during 
infection actually betters clinical outcome in experimental S. pneumoniae infection. The 
final step in PMN luminal trafficking is a Hepoxilin A3 (HXA3)-dependent migration 
across the pulmonary epithelium. HXA3 is a PMN chemoattractant that forms gradients 
along the polarized epithelial face, drawing PMNs from the basolateral to the apical 
surface during proinflammatory responses. HXA3 requires assistance of an integral-
membrane protein transporter to escape the cell and form the gradient. The pulmonary 
HXA3 transporter is currently unidentified.  
In this work, we identify the pulmonary HXA3 transporter as the ATP-Binding 
Cassette Transporter (ABC transporter) Multi-drug Resistance Associated Protein 2 
(ABCC2, MRP2). We demonstrate that MRP1 and MRP2 are divergent ABC-
transporters that control transepithelial PMN migration through efflux of a distinct anti-
inflammatory substance and the pro-inflammatory HXA3 in the context of Streptococcus 
pneumoniae infection. Enrichment of MRP2 on the plasma membrane requires detection 
of the bacterial virulence factors pneumolysin (PLY) and hydrogen peroxide. PLY and 
hydrogen peroxide not only coordinate MRP2 apical membrane enrichment but also 
influence HXA3-dependent PMN transepithelial migration. They influence migration 
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through stimulation of epithelial intracellular calcium increases that are crucial for HXA3 
production as well as MRP2 translocation to the plasma membrane. PLY and hydrogen 
peroxide are not sufficient in their signaling alone, however, and require at least one 
additional bacterial signal to induce HXA3/MRP2 proinflammatory activities.   
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Chapter I 
Introduction 
 
1.1 Infection and neutrophil infiltration 
The microbiome is a critical component of healthy intestinal and immune 
systems. The symbiotic microbes provide training for our immature immune system at 
early ages, provide metabolites from different biochemical processes, and form physical 
barriers preventing pathogenic bacteria from gaining a foothold in our mucosal systems.  
When pathogens do break through, they initiate host immune responses that 
combat infection through a variety of methods. The innate immune neutrophils (PMNs), 
granulocytes, macrophages, and dendritic cells (DCs) are the cellular components that 
immediately attempt to control the infection through relatively non-specific means. In 
particular, PMNs are the most abundant and effective innate immune cells that respond to 
bacterial invasion of the host. To enter the infected site, PMNs are recruited from the 
vasculature, through the endo- and epithelial cell layers, and are finally able to combat 
the bacterial challenge in the lumen of the organ. While much is known about 
transendothelial recruitment of PMNs, such as the need for NF-κB and attachment 
molecule expression (1), less is known about transepithelial movement. Classically, 
PMNs are activated through a combination of chemoattractants released into the blood 
stream in close proximity to the site of infection. These chemoattractants assist in 
activating selectin tethering molecules in both the endothelium and the PMNs to induce a 
process of “rolling”. As the PMNs adhere to the endothelium, they are further activated 
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by heparan sulfate proteoglycans (2). PMNs release metalloproteases and other 
degradation molecules to degrade the extracellular matrix as they transcytose both para- 
and trans-cellularly through the endothelium.  
To progress from the endo- to epithelial cell layer, IL-8 and other NF-κB-
dependent cytokines draw PMNs from the circulation towards the basolateral portion of 
the epithelium (3) while lipid Hepoxilin A3 (HXA3) draws PMNs from the basolateral 
surface to the apical surface (4). Basolateral docking of the PMN to the epithelium 
appears to be the initial stage by which epithelium tight-junction disintegration occurs 
(5). Once in the lumen, PMNs act by phagocytosing bacteria and then using oxidative 
burst, proteases, and Neutrophil Extracellular Traps (NETs) to eliminate bacterial 
invaders. PMNs also use secreted reactive oxygen metabolites that both injure bacteria 
and tissue in the surrounding area. Some predominant proteases released and activated 
during PMN excitation are elastases, proteinase 3, and capthepsin G that assist in 
degradation of extracellular membrane components and intracellular digestion of 
phagocytosed bacteria (6). One of the most critical molecules in charge of drawing PMNs 
to the site of infection is the epithelial-cell derived chemoattractant HXA3. 
 
1.2 HXA3-mediated PMN migration  
HXA3 was originally identified as an arachidonic acid metabolite that influences 
insulin release in pancreatic islets of Langerhans (7). It has been identified to have roles 
in liver (8), neuronal biology (9), an activator of calcium mobilization, and activation in 
PMNs (10). Originally identified as PEEC, McCormick et al. described a bioactive lipid 
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mediator of PMN migration elicited from epithelial cells during infection with 
Salmonella enterica Typhimurium, later identified to be HXA3. In the years since, HXA3-
dependent PMN migration has been observed during intestinal infection with Shigella 
flexneri (11), E. coli (12), and as a component of PMN infiltration during active 
inflammation in Inflammatory Bowel Disease (IBD) (13).  
 With the identification of this process being widespread in different intestinal 
infections, additional research inquired as to the HXA3 dependency during PMN 
infiltration at other mucosal sites. The ocular, pulmonary, and urogenital tract all require 
similar epithelial cell layers to segregate exposure to the outside world from the relatively 
sterile internal system of the host. To that end, we examined whether the HXA3 pathway 
is conserved in the pulmonary system, which is subject to dysbiosis similar to the 
intestine in the form of bacterial infection, Chronic Obstructive Pulmonary Disease 
(COPD), and Acute Respiratory Distress Syndrome (ARDS), to name a few.       
The upper respiratory system, which includes the nasopharynx and entry to the 
trachea, has its own natural microbiota and commensal bacteria. These bacteria tend to be 
both harmless, resident bacteria as well as opportunistic bacteria such as Haemophilus 
influenzae and Streptococcus pneumoniae. Respiratory pathology due to these 
opportunistic bacteria classically begins with invasion of the lower respiratory system. 
Macroscopically, there are two distinct regions of the lower respiratory system: the 
bronchus/trachea and alveolar-containing region of the lung. Each region has a distinct 
distribution of specialized epithelium. For instance, the bronchus region contains ciliated 
epithelium, secretory clara, goblet cells, and basal cells. As the pulmonary system 
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narrows towards the alveolar spaces, there is a trend toward fewer secretory cells and an 
increase in the alveolar type I and type II epithelium.  
The epithelium forms a physical barrier between the pulmonary lumen and the 
endo-/epithelial basement membrane. Epithelial cells are held together by a variety of 
connections, including gap junctions, desmosomes, adherence junctions, and tight 
junctions. The Claudin family of proteins reinforces many of these connections. The tight 
junctions allow for the classic delineation between the lumen-facing apical portion of the 
epithelium, and the basolateral surface. During inflammation, there are a number of 
cytokines, such as IL-4 and IL-13 that reduce tight junction integrity and increase 
permeability (14). As in the intestine, PMNs exit the vasculature and migrate into the 
pulmonary lumen in a HXA3-dependent manner. The activity of IL-8 appears distinct 
from HXA3, as IL-8 is critical during the inflammatory process to draw PMNs to the 
basolateral surface of the epithelium but does not appear to influence the transepithelial 
migration from basolateral-to-apical surface (3). 
Hepoxilin synthesis begins with the activation of Protein Kinase C (PKC) and 
Phospholipase A2 (PLA2), stimulating release of arachidonic acid from the membranes of 
the epithelium into the cytoplasm (11, 15-17). 12/15-lipoxygenase converts the 
arachidonic acid to Hepoxilin A3, which is effluxed to the apical surface of the epithelium 
and creates a chemotactic gradient through the epithelial cell layer to attract PMNs 
through the tight junctions (Figure 1.1). Hurley et al. found that Pseudomonas aeruginosa 
induces HXA3-dependent PMN migration during infection of lung cells in vitro, much 
like bacterial infection of the intestine (18). Likewise, Bhowmick et al. reported that S. 
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pneumoniae is able to elicit PMN migration from infected epithelium, and that this effect 
is curtailed by ablating Lox15, the 12/15-Lipoxygenase gene from mice (19). Such 
studies illuminate several specifics of the HXA3 cascade and signaling process: first, this 
appears to be a conserved process across different mucosal surfaces, as similar effects 
occur in both the lung and intestine; second, HXA3-dependent PMN migration is not 
isolated to Gram-negative bacteria because it occurs with the Gram-positive S. 
pneumoniae; third, HXA3 is induced by both intracellular and extracellular pathogens, 
Despite these observations, there have been few reports of individual virulence factors 
that influence the production and release of HXA3 from infected epithelial cells.  
Salmonella Typhimurium requires expression of genes from pathogenicity island 1 (SPI-
1) for both epithelial invasion as well as infection-driven HXA3 efflux. The SPI-1 
virulence factor SipA is one of specific factors required for HXA3-induced PMN 
migration (20). With exception to this report, the mechanism of HXA3 induction by 
bacterial pathogens is not known. 
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Figure 1.1 Model of HXA3 induction 
During infection, bacteria, such as Streptococcus pneumoniae, encounter the apical 
surface of the epithelium that is held together with a variety of junction proteins. 
Bacterial components engage TLR receptors and induce NF-κB signaling which produces 
IL-8 in addition to a number of other pro-inflammatory signals. These signals initiate 
PMN escape from the vasculature to the basolateral surface of the epithelium. In a 
separate set of events, PLA2 activates and releases arachidonic acid. This is converted to 
HXA3 and effluxed to the apical surface of the epithelium, forming a chemotactic 
gradient that attracts PMNs to the lumen of the organ. 
Transporter 
HXA3 
HXA3 
HXA3 
12/15 
Lipoxygenase 
Hepoxilin A3 
(HXA3) 
Arachidonic 
Acid NF-κB   
IL-8 
PLA2 
Streptococcus 
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1.3 ABC-transporters 
 In both the intestine and the lung, the upstream epithelial machinery controlling 
the synthesis of HXA3 is similar. PKC and PLA2 are needed to release arachidonic acid 
and produce HXA3 via 12/15-lipoxygenase activity, regardless of the epithelial cell 
origin. One critical aspect of HXA3 release is that it does not passively transverse the 
plasma membrane but is pumped by a specific efflux transporter. Using both inhibitor 
studies and siRNA, the intestinal HXA3 transporter was identified as the Multi-Drug 
Resistance associated Protein 2 (MRP2, or ABCC2) (13).  
 MRP2 belongs to a family of transmembrane ATP-Binding Cassette Transporters 
(ABC-Transporters) that hydrolyze ATP into ADP and expel or import payload across a 
membrane bilayer. Naming of the ABC-transporters usually employs the “Multi-Drug-
Resistance Protein” (MDR) or “Multidrug-Resistance-associated Protein” (MRP) 
nomenclature. These molecules are highly conserved throughout bacteria and eukaryotes, 
though the ligand interactions are both diverse and promiscuous. While bacterial 
transporters tend to be exclusively found on the exterior membrane, eukaryotes have 
transporters embedded on vesicles or internal organelles, as well as the exterior 
membrane bilayer. 
 Normally, ABC-transporters primarily function to efflux xenobiotics that enter the 
cells. Cells most likely to encounter toxins and xenobiotics are those mucosal surfaces 
that frequently come in contact with substances from the surrounding environment: the 
intestine, lung, and urogenital tract, among others. ABC-transporters are detected in 
many other tissues, including the blood-brain-barrier, adrenals, heart, kidney, liver, 
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ovaries, pancreas, placenta, prostrate, skin, spleen, and testes (21). Subcellularly, ABC-
transporters have been found on both the apical and basolateral portions of the epithelium 
as well as the plasma, peroxisomal, endosomal, lamellar body, and lysosomal membranes 
(22). ABC-transporters tend to localize to specific faces of polarized cellular barriers: 
MRP2, for instance, is almost exclusively found on the apical surface of the epithelium, 
whether in the liver, lung, or intestine. In contrast, MRP3 in the intestine is almost 
exclusively on the basolateral surface of the epithelium (Figure 1.2).  
 Structurally, ABC-transporters contain three domains: transmembrane, linker, and 
nucleotide-binding (NTB) domains. The transmembrane domains make up the body of 
the protein pump and the recognition sites for ligands while the NTB domains provide 
pockets for ATP and ADP binding. Linker regions are physical connections that join 
different transmembrane or NTB domains to one another. ABC-transporters tend to be 
either of the shorter variety (12-to-14-transmembrane domain long), or longer (17-
transmembrane domains). Shorter pumps have cytosolic amino terminals while longer 
pumps have extracellular amino terminals (23). During activation, a ligand encounters the 
active pocket of the transporter, usually at the cytosolic face, and then allows ATP to 
bind the NTB site. ATP hydrolysis induces a conformational change in the 
transmembrane domain, forcing the ligand to the extracellular face of the transporter. The 
ADP interaction with the NTB domain reduces the binding affinity for the ligand and it is 
released, allowing the ABC-transporter to reset and repeat. ABC-transporters are able to 
undergo post-translational modifications, including glycosylation (24), SUMOylation 
(25), and phosphorylation (26).  
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Figure 1.2 Schematic of ABC-transporter location on polarized epithelial  
ABC-transporters tend to locate to specific faces on polarized epithelium. MDR1 (P-gp), 
for instance, localizes almost exclusively to the apical surface of polarized intestinal 
epithelium. Conversely, MRP1 is almost exclusively basolateral in the intestine. Less is 
know about the location of the ABC-transporters in the lung. Arrows indicate the face the 
transporter is normally located in the given organ. Circles indicate that the transporter is 
found in intracellular vesicles. “?” denotes conflicts in the literature. Bronchus and 
Alveolar localization modified from van der Deen 2005 (27).   
MRP4 
MRP1 MRP5 MDR1 MRP2 MRP3 MRP4 Intestine 
Bronchus 
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 Due to its propensity to efflux toxins and xenobiotics, ABC-transporters are most 
known for conferring multi-drug resistance to chemotherapeutic agents. There are many 
studies indicating a correlation between ABC-transporter expression and worsening 
chemotherapeutic resistance in a variety of cancers (28). While ABC-transporters have a 
somewhat promiscuous nature, not all transporters are able to efflux the same ligands. P-
glycoprotein (P-gp), for instance, is able to efflux hydrophobic molecules as well as 
vinblastine (27). MRP4 effluxes nucleoside analogs and organic anions (29). Likewise, 
there are specific inhibitors that target one ABC-transporter but not the others. There are 
entire studies focused specifically on eliminating targeted MRPs or MDR proteins in 
unique chemotherapeutic-resistant carcinomas, and there is a wealth of knowledge on 
inhibition and ABC-transporter activity in the context of cancer chemotherapeutics. In 
contrast, there is a dearth of knowledge on the endogenous activity of these transporters.  
 
1.3 Efflux Transporters and their contribution to inflammation 
The majority of ABC-transporter research outside the context of cancer 
chemotherapy has focused on the intestine. This focus was stimulated by the observation 
that mice deficient in the efflux pump P-gp develop spontaneous colitis (30). P-gp 
knockout mice now serve as model for Inflammatory Bowel Disease (IBD).  
P-gp is a smaller, 12-pass transmembrane efflux pumps localized to the apical 
surface of the intestine. It transports hydrophobic, positive-, or neutral-charge 
compounds. Elimination of this gene leads to a hyper-inflammatory phenotype, 
supporting the supposition that P-gp suppresses basal inflammation and assists in 
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microbiome equilibrium. P-gp is not only found on the epithelium but also on leukocytes. 
One study in 1999 examined P-gp expression on different leukocyte subtypes and noted 
decreases in P-gp activity in ulcerative colitis (UC) patients compared control subjects 
(31). In addition, a 2006 meta-analysis revealed that certain P-gp alleles are associated 
with severe UC (32, 33). Independent of IBD-associated diseases, P-gp is also known to 
be targeted by bacteria during infection; studies have shown that the Salmonella secreted 
protein SipA cleaves P-gp and may play a central role in bacterial attachment (34). 
Another ABC-transporter that has associations with inflammation is Multidrug 
Resistance- associated Protein 1 (MRP1 or ABCC1). MRP1 is a 17-transmembrane-
domain protein that localizes to the basolateral portion of the intestinal epithelium. The 
substrate specificity of MRP1 encompasses glutathione-, glucuronide-, and sulfate- 
conjugated organic anions; drugs vincristine, daunorubicin, and methotrexate; and 
Leukotriene (LTC4), as well as glutathione disulfide. Studies indicate that MRP1 may be 
increased during episodes of IBD (35), which could lead to increased secretion of the 
pro-inflammatory mediator LTC4. LTC4 is an eicosanoid that increases mucus secretions 
and can cause vasoconstriction and vasodilation, but can also induce leukocyte rolling via 
P-selectin induction. Another leukotriene, LTB4, primarily assists in leukocyte 
extravasation activation. Studies conducted by Tessa Tan Hove also suggest that LTB4 
and LTC4 are increased during TNBS-induced colitis. In the same study, MRP1 knockout 
mice had less inflammation and less cellular damage as compared to wild-type mice 
during times of TNBS-induced intestinal inflammation, but were more susceptible to 
ethanol- or Dextran sulfate sodium (DSS)-induced damage than wild-type mice (36). 
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DSS-induced colitis was substantially worse in Mrp1-/- mice compared to their wild-type 
counter-parts, causing both severe pathology and decreased survival. During this time 
period, there was an observed increase in LTB4. Because LTB4 and LTC4 both share a 
common precursor, it was postulated that a decrease in MRP1 could lead to a decrease in 
LTC4 and, therefore, an increase in LTB4 as more LTA4 is sequestered to that pathway. 
Application of an LTB4 inhibitor did not improve outcomes, suggesting that LTB4 
increases due to MRP1 elimination may not be the only contributing factor in this 
particular model (36). The study did not include an examination on the possible effects of 
exogenous LTC4 application, so it remains to be seen whether LTC4 could relieve the 
increased DSS-sensitivity, though addition of a pro-inflammatory agent to relieve 
inflammation seems paradoxical. The MRP1 increase during IBD seen in patients could 
be compensatory.  
Other aspects of MRP1 expression that point to a protective role are the effects of 
Tissue Necrosis Factor–α (TNF-α). Overexpression of MRP1 has been shown to protect 
cells during exposure to TNF-α or FAS-ligand (35). Studies in glial cells showed that 
MRP1 might be upregulated during exposure to TNF-α in a JNK-dependent manner (37). 
Additionally, Blokzijl et al. detected MRP1 overexpression during cytokine- and FAS-
induced apoptosis and noted that epithelial cells that overexpress MRP1 showed lower 
levels of apoptosis compared to wildtype controls (35). Epithelial cell death is a hallmark 
of DSS-induced colitis and thought to be an initiating step that degrades barrier integrity 
and allows the microbiota to induce inflammation. Increase of MRP1 would reduce cell 
death and stabilize barrier integrity, thereby reducing the permeability of the epithelial-
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wall structure. Oxidative stress, too, has been implicated in exacerbation of damage in 
IBD while glutathione, a known ligand of MRP1 (38), is known to quench oxidative 
stress. Increasing MRP1 may quench oxidative stress during times of intestinal 
inflammation via GSH excretion. An MRP1 increase would neutralize oxidative stress. 
Without this increase, epithelial damage in models of IBD would be exacerbated.  
When inspecting specific leukocytes, expression of MRP1 has been shown to 
increase on the surface of macrophages during exposure to lipopolysaccharide (LPS), 
though there has been no extensive work examining the endogenous actions of MRP1 on 
these cells (39). While no specific studies have linked MRP1 and DC activation to IBD or 
other inflammatory conditions, MRP1 is critical for DC maturation, and this could also 
impact TNF-α expression and leukocyte migration to the site of inflammation (40).  
P-gp and MRP1 have implied anti-inflammatory effects that appear to protect the 
epithelium from excess inflammatory stress. MRP2, unlike P-gp and MRP1, has 
exhibited very clear pro-inflammatory activity. Several substrates overlap between MRP2 
and MRP1, though the localization of MRP2 is typically apical in contrast to the 
basolateral localization of MRP1. MRP2 substrates include amphiphilic anions, bilirubin, 
glucuronosides, LTC4, and the aforementioned HXA3. MRP2 is highly expressed in the 
intestine, kidneys and liver of mammals. While elimination of MRP2 leads to Dubin-
Johnson syndrome, highlighted by a state of hyperbilirubinemia, there is sparse 
information about the role of MRP2 in IBD and related diseases. In studies conducted in 
rats, basal MRP2 protein and mRNA expression decreased descending from the 
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proximal-to-distal intestine, meaning that the highest expression was in the small 
intestine and decreased descending towards the colon (41).  
During Salmonella infection of mice, Pazos et. al reported that MRP2 increased, 
presumably to release HXA3 (13). In this same study, mice underwent T-cell transfer and 
were treated with a lipoxygenase inhibitor, which alleviated much of the inflammation 
observed in mock-treated animals. In addition to examination in mice, intestinal sections 
of patients suffering from IBD also exhibited increased MRP2 signaling via 
immunofluorescence (13). MRP2 increase could promote PMN influx during the onset of 
IBD, creating a pro-inflammatory condition. While influx would not be seen as aberrant 
during a bacterial infection, an uncontrolled response by PMNs without exposure to a 
stimulus could lead to host-tissue damage. HXA3 secretion by MRP2 could lead to PMN 
transmigration, activation, and subsequent epithelial damage as seen in IBD; it is 
therefore possible that targeting MRP2, and the subsequent inhibition of HXA3, may be 
therapeutic.  
It is known that E. coli that express Shiga-toxin II (Enterohemorrhagic 
Escherichia coli, or EHEC) reduce expression of both P-gp and MRP2 in the kidneys and 
livers of patients (42), whereas E. coli without Shiga-toxin, a strain of Enteroaggregative 
E. coli, upregulate MRP2 expression in the gut and assists in PMN migration (12). 
Similarly, Shigella flexneri also upregulates MRP2 during infection, implying that Gram-
negative intestinal pathogens may cause MRP2 increases during infection by some 
common mechanism and that it is  Shiga-toxin independent. 
		
15	
In contrast to findings with MRP1, it has been shown in rat hepatocytes that TNF-
α may reduce the expression of MRP2 (42). Additionally, it has been shown that liver 
cells exposed to LPS from Gram-negative bacteria may also reduce MRP2 protein (43). 
In contrast, bacterial infection increases MRP2 protein in intestinal infections, 
emphasizing tropism differences in eukaryotic cells. There is no report of MRP2 
expression in leukocytes during resting states or infection, indicating epithelial cells are 
the most likely to be impacted by varying MRP2 expression.  
One transporter that has been studied but not shown to have many critical 
activities in the context of bacterial inflammation is Multi-drug-Resistance-associated-
Protein 4 (MRP4). MRP4 effluxes nucleoside agents, Prostaglandins 1 and 2, organic 
anions, bile acids, and folic acid. It is purported to localize on both the apical and 
basolateral surface of intestinal epithelial cells. Prior reports have shown that MRP4 is 
important in its interactions with chemicals commonly used to treat IBD, specifically 
thiopurines (44). Japanese patients with a allelic mutation of MRP4, G2269A, showed 
increased sensitivity to thiopurines because MRP4 is incapable of pumping it out of 
myeloid cells. These patients also showed lower white-blood-cell counts than wild-type 
allelic control patients with IBD, though there does not appear to be any direct correlation 
between this and any reduction in auto-immune diseases (44). Additionally, a recent 
publication examined a downregulation of MRP4 during IBD in the context of bile-acid 
reabsorption perturbations (45). Copies of MRP4 mRNA were reduced in endoscopy 
tissue isolated from older IBD patients as compared to healthy colons. In recent years, 
there has also been emerging information on MRP4 efflux of LTC4 (46). 
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MRP4 was previously reported to be critical during DC migration, however van 
der Deen and colleagues noted that murine DC movement had no dependency on MRP4 
(40). In the same study, inhibition of dendritic-expressed human MRP4 led to a reduction 
in migrating DCs in skin explants and in vitro-derived Langerhan cells. Any links 
between MRP4, dendritic cells, and IBD must take into account differences between 
murine and human data. 
 
1.4 ABC Transporters in the Lung 
 While research into the activity of ABC-transporters in the intestine has 
illuminated roles for this family of proteins, the digestive tract is only one particular 
mucosal surface. Recently, details have emerged as to the activities and expression 
patterns of ABC-transporters elsewhere, especially the lung. As this field is still evolving, 
there remains controversy about expression and localization of the various pulmonary 
transporters. For instance, a review by Margaretha van der Deen indicates that conflicts 
about localization of the MRPs in Type I epithelial cells exist for MRP1, MRP2, MRP3, 
MRP4, MRP5, P-gp, and CFTR (27). Much of this divergence centers on the low 
expression of these proteins in the lung at basal level and how expression can subtly 
change depending on the method of examination and how the lung is processed.  
 There are observations that appear to be consistent between studies. P-gp has a 
relatively low expression in the lung; it is thought to be present in the bronchus and 
trachea but absent as the airway constricts. Although the role of P-gp in the lung remains 
unknown, it has been shown that P-gp expression is increased in smokers as compared to 
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non-smokers. In in vitro lung cell lines, while Calu-3 and A549 cell lines express P-gp, it 
appears absent in H292 cells (Figure 1.2).  
 MRP1 is mRNA and protein is detectable in pulmonary tissue (27), though it is 
unclear whether MRP1 is expressed consistently on the apical surface of epithelial cells 
or strictly on the basolateral surface. Although there have been reports of no change in 
mRNA levels of MRP1 during COPD and smoking studies, there have been separate 
observations of MRP1 protein level reductions in COPD patients (47). There are also 
indications that MRP1 could be protective during inflammation caused by COPD (47). 
Mycobacterium tuberculosis-infected mice deficient in Mrp1 have higher bacterial 
burdens as compared to wild-type mice, though there is no difference in survival between 
the two groups (48). There has also been investigation involving Mrp1-knockout mice in 
Streptococcus pneumoniae infection in which Mrp1-knockout mice showed increased 
survival as compared to infected wild-type mice (49). This work is discussed later in 
Chapters 2 and 4. MRP1 is known to efflux LTC4 and may influence LTB4 release from 
cells, a fact that was reported in the context of PMN infiltration during S. pneumoniae 
infection (49). Expression of MRP1 is one of the many proteins controlled by the 
transcription factor NRF2. Nrf2-knockout mice developed earlier and more severe 
emphysema during smoking studies with more leukocyte, especially macrophage, 
infiltration (50).  
 There is little known about the role of MRP2 in the lung and there are debates as 
to where and in what contexts MRP2 is expressed in lung tissue (27, 51). In most studies, 
it is almost undetectable in the absence of inflammation and is much more studied in the 
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context of lung carcinomas than at basal, non-pathogenic states. Likewise, MRP3 appears 
almost undetectable in pulmonary tissue, although it is highly expressed in the liver, 
adrenal glands, pancreas, kidney, intestine, and gall bladder (27). Increases in MRP3 in 
the human lung are more often associated with tumor development. The activity of MRP3 
in non-tumor pulmonary tissue is still unknown. MRP5 has been confirmed to be 
expressed in pulmonary tissue but the activity and localization is still undetermined (27).  
 MRP4 has similar activity in the lung and other tissues, such as brain and skeletal 
muscle. It is known to efflux PGE1 and PGE2 that assist in modulating the immune 
system (52). In light of that, however, a number of studies have concluded MRP4 does 
not act in a variety of immune stimuli. For instance, a 2013 study reported no differences 
in PMN or eosinophil recruitment in the lung during LPS, allergen, or cigarette smoke 
challenges (53). To that end, while it is known that the lung expresses MRP4, it remains 
to be seen how dramatically it is able to impact endogenous pulmonary immune function.  
 It would be imprudent not to recognize another major ABC-transporter in the 
lung, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). Though CFTR 
does not behave as the other ABC-transporters on this list, it is significant in pulmonary 
physiology. While the MRPs pump a variety of drugs and are widely known for 
conferring chemotherapeutic resistance, CFTR is a chloride channel that opens and closes 
during respiration. Cystic Fibrosis is a disease that occurs when a CFTR mutation leads to 
chloride retention in the epithelium, resulting in a buildup of mucus in the pulmonary 
tract. This leads to obstruction of the air way and results in frequent bacterial infections. 
CFTR does not directly result in the modulation of the immune system but certainly 
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modifies the microenvironment, providing a niche for bacteria such as Pseudomonas 
aeruginosa.  
 
1.5 Streptococcus pneumoniae  
S. pneumoniae (pneumococcus) is a Gram-positive, encapsulated bacterium that 
normally colonizes the human nasopharynx asymptomatically. Although pneumococcus 
is permissible to other organisms, such as rodents or other mammals, the natural reservoir 
seems to be Homo sapiens. Depending on given locations and regions of habitation, up to 
90% of human population will, at one time, have S. pneumoniae inhabiting their 
respiratory system.  
There are currently two available pneumococcal vaccines that are administered to 
children before two years of age. These vaccines target serotypes of S. pneumoniae, as 
identified by the glycan composition of the pneumococcal capsule. The vaccines target 
13- and 23-polyvalent capsular serotypes, which encompass many of the clinically 
relevant pneumococcal strains. Problematic to the healthcare sector, the capsule is highly 
divergent and there are over 100 capsule isolates, meaning there are some serotypes that 
are not protected by the current vaccine regimen. In addition, S. pneumoniae goes 
through certain phase transitions during infection where the acapsular bacteria are 
predominant in specific regions of the respiratory system (54).  
Although pneumococcus can inhabit the nasopharynx asymptomatically, 
problems arise when bacteria enter the lower respiratory system. Initially, infection can 
lead to inflammation, presenting clinically as pneumonia. Pathology can progress from 
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lung infection and enter the blood stream leading to the development of bacteremia and 
sepsis. S. pneumoniae can also cross the blood-brain-barrier and cause meningitis. Prior 
to introduction of the polyvalent pneumococcal vaccine, invasive disease rates for 
children under the age of 5 approached 100 cases per 100,000 as reported by the CDC 
(55). This dropped sharply by approximately 60% after introduction of the pneumococcal 
vaccine and is currently ~10 per 100,000 in the United States (55). This means, though, 
that almost 400,000 cases of pneumococcal pneumonia are reported annually to the 
Centers for Disease Control (56). It is reported that 25-30% of these pneumonia patients 
develop pneumococcal bacteremia, a condition that has a case-fatality rate of 20% 
(though, this is closer to 60% in elderly individuals) (56). Complications from infection 
can also lead to brain injury, amputations, and multi-organ dysfunction.  
A number of virulence factors assist in asymptomatic colonization and persistence 
of S. pneumoniae. More information about specific pneumococcal virulence factors and 
the interactions with the host epithelium as well as other resident bacteria can be found in 
two extensive reviews: the first in 2008 by Aras Kadioglu (57) and the second from 
Mook-Kanamori in 2011 (58). It is important to note that normal transmission of S. 
pneumoniae is not contingent on diseased state: S. pneumoniae can equally be transmitted 
by asymptomatic carriers as well as actively diseased individuals. Many of the virulence 
factors that mediate pathology are originally utilized to assist in asymptomatic carriage. It 
is widely accepted that a number of bacterial factors, such as pneumococcal 
phosphorylcholine and Choline-binding Protein A, are able to bind specific receptors on 
the surface of the epithelium and assist in adherence or internalization of the bacterium 
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(59-61). Hyaluronate lyase released by S. pneumoniae is able to degrade extracellular 
matrix components (62). Still others, like Pneumococcal Adherence and Virulence factor 
A and α-Enolase bind fibronectin and plasminogen, respectively (63, 64). Pneumococcal 
neuraminidase A cleaves terminal sugars, which may reveal adherence molecules, 
provide carbon sources for energy generation, or assist in biofilm formation. 
Neuraminidases also cleave mucin, which may reduce mucin density and allow the 
bacteria to form a niche for growth much easier.  
One of the most widely-studied virulence factors, the cholesterol-dependent-
cytolysin pneumolysin (PLY), has many effects, including disrupting ciliary beating to 
allow bacteria to form a static niche within the mucosal surface. To combat secreted host-
defenses, Pneumococcal Surface Protein A prevents complement C3 deposition and lysis 
of the bacteria while pneumococcal IgA cleaves resident IgA1 that might affect the 
bacteria.  
S. pneumoniae not only faces pressure from the host but also from other resident 
bacteria. To defend itself from other bacteria, S. pneumoniae produces bacteriocin, an 
antimicrobial molecule that targets other species and even other strains of Streptococcus 
(65). One of the more unique virulence factors is pneumococcal hydrogen peroxide. Most 
bacteria harbor catalase to neutralize hydrogen peroxide, but because S. pneumoniae does 
not have an endogenous catalase, hydrogen peroxide builds up to (potentially) hazardous 
levels for surrounding bacteria. Haemophilus influenzae, for example, is unable to grow 
in vitro in the presence of pneumococcus unless an exogenous catalase is present during 
growth stages (66). Unique to S. pneumoniae in the context of this study is that, unlike 
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many of the other Gram-negative bacteria mentioned previously, S. pneumoniae doesn’t 
have a classic secretion system. To release soluble virulence factors, it is presumed that 
the bacteria must self-lyse. In a coordinated but not altogether understood process, LytA, 
a lytic-initializing gene activates and causes the bacteria to lyse (57). In the case of PLY, 
it is thought that autolysis assists in releasing PLY to the extracellular milieu, though this 
is contentious as certain serotypes do not appear to need autolysis to release PLY (67). 
Autolysis would also release intracellular hydrogen peroxide that accumulates during 
normal metabolism.  
S. pneumoniae also needs to defend itself from innate host defenses. Although 
pathology is not normally observed in nasopharyngeal carriage, resident leukocytes still 
respond by attempting to engulf bacteria. During carriage, other bacterial species may 
also try to form niches in the nasal passage. This highlights the two-front arms race that 
S. pneumoniae enters when colonizing. To neutralize the eukaryotic defenses, 
pneumococcus has an immunogenic capsule that prevents mucus entrapment and 
opsonization from white blood cells (68). Somewhat ironically S. pneumoniae employs a 
number of different mechanisms to avoid killing by PMNs, rendering the overall PMN 
response necessary in the early stages but also highly inefficient. S. pneumoniae is 
primarily killed via elastase and cathepsin G (69), though van der Windt and colleagues 
recently determined that acapsular pneumococcus are more resistant than their 
encapsuled counterparts (70). EndA, an endonuclease, is also thought to provide protect 
from PMN NETs as it degrades DNA. D-analynation of lipoteichoic acid (modifying 
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lipoteichoic acid with D-alanine) also confers some resistance to NETs via electrostatic 
repulsion of the anti-microbial peptides contained there within (71).  
 PMN activity is necessary to contain the initial pneumococcal infection and 
combat the infection through a variety of non-specific ways, such as release of granules, 
ROS, anti-microbials, and activation of humoral cytokines. The tradeoff of this activity is 
that it causes potential damage to both the bacteria and the surrounding healthy 
pulmonary tissue. There is a growing body of literature to suggest that either PMN 
activity or epithelial transcytosis itself could cause gaps in the paracellular junctions, 
permitting bacteria to reach the underlying basement membrane and then travel through 
the endothelium to the blood stream, causing bacteremia (Discussed in greater detail 
Chapter II). Blood infection is also e pre-requisite for bacteria to cross the blood-brain-
barrier and cause meningitis. One viewpoint supports that by limiting entry of the PMNs 
in the lumen of the lung, without eliminating PMNs entirely, the host might be able to 
control the infection without subjecting the pulmonary tissue to collateral damage. 
Numerous reports have shown that if PMN infiltration is suppressed, murine infections 
fail to progress as quickly to bacteremia, if at all (19, 72, 73). Given that HXA3 is critical 
in lumenal PMN migration, one desire of our studies was to identify potential targets 
involved in HXA3-mediated transepithelial migration and to assay whether inhibition of 
these new targets would recapitulate the previously observed reduction in bacteremia.  
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1.6 Thesis summary: How is HXA3 effluxed during pulmonary infections and what 
virulence factors impact this/these efflux transporter(s)? 
The foundational work that influenced this particular thesis project described S. 
pneumoniae-induced PMN migration as HXA3-dependent (19). The second identified 
MRP2 as the HXA3 efflux transporter in the intestine (13).  In comparing and contrasting 
the HXA3 effects in the lung and the intestine, studies show that all of the bacterial 
species investigated initiate the release of arachidonic acid via PLA2 and that arachidonic 
acid is processed by 12/15-lipoxygenase. It is currently unknown, however, how the 
HXA3 is effluxed from the pulmonary epithelium, whether by MRP2 or another, similar, 
transporter. As stated in section 1.4 and 1.5, there are a number of possible ABC-
transporters that could be contributing to immune modulation in the lung during S. 
pneumoniae infection.   
The identification of the HXA3 efflux transporter is critical for future therapeutic 
and intellectual endeavors focusing on PMN inflammation. Bhowmick et al. describes 
not only that HXA3 is critical for PMN infiltration during S. pneumoniae infection but 
also bolsters previous findings that there is a correlation between dissemination of S. 
pneumoniae and PMN infiltration. However, targeting HXA3 and its synthesis gene, 
12/15-Lipoxygenase, is challenging, as these are intracellular processes that could have 
multiple off target effects. Efflux transporters, on the other hand, are surface-exposed 
targets that have relatively localized expression patterns. In addition, there are multiple 
drugs approved for human use targeting these efflux transporters, making it a strong 
drug-repurposing candidate. If the efflux transporter is the same as in the intestine, 
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MRP2, it points to the conserved nature of systemic mucosal immunity. If it is different, 
it emphasizes that tropic uniqueness could be key to targeting specific therapies for 
localized inflammation/anti-inflammation interventions. Either answer would yield a 
wealth of information with which one may move forward examining how PMNs infiltrate 
the mucosal lumen during inflammatory events.  
Likewise, identifying the virulence factors that affect this/these transporters(s) is 
critical to establish how conserved the HXA3 pathway and efflux activity is across a 
variety of mucosal surfaces. By identifying those S. pneumoniae virulence factors that are 
critical for HXA3 and PMN transepithelial migration, additional eukaryotic targets 
critical to transepithelial PMN migration might be identified. By identifying common 
pathways between S. pneumoniae infection and the prior identified intestinal 
inflammatory events, universal pro-inflammatory pathways could come to light. 
To investigate the pulmonary HXA3 transporter and S. pneumoniae virulence 
factors that influence PMN transepithelial migration, the specific aims that we will be 
examining are the following: 
 
1) What efflux transporters are modulated during S. pneumoniae infection? 
 a. Is MRP2 the efflux transporter in pulmonary infections or is it a 
different transporter? 
 b. Are there other transporters involved in the process? 
 c. Will manipulation of the efflux transporter yield similar phenotypes as 
the blockade of HXA3 expression in in vitro and in vivo experiments? 
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2) What virulence factors might be influencing the efflux transporter? 
 a. Can we identify the specific players that are critical for PMN migration? 
 b. Is there a common thread between the S. pneumoniae virulence factors 
and other bacterial virulence factors that are important for HXA3? 
 c. What upstream eukaryotic pathways or secondary signals might be 
triggered by these virulence factors to influence the HXA3 transporter/PMN migration? 
 
We set out to initially to identify the efflux transporter assisting in the generation 
of HXA3 gradients during S. pneumoniae infection. We took a semi-biased screening 
approach to examine the pulmonary Multi-drug-Resistance associated Proteins that are 
modulated during infection with S. pneumoniae. We then assessed the likely role of each 
MRP that changed during the infection. We discovered that during infection with S. 
pneumoniae, apical MRP1 is reduced while MRP2 increases its presence on the plasma 
membrane apical surface. After identifying MRP1 and MRP2 as proteins of interest, we 
examined the likely role they played in infection. We specifically focused on suppressing 
the PMN infiltration through inhibition of MRP2 and tracked any changes in disease 
progression in mice infected with S. pneumoniae.  
To elucidate how S. pneumoniae influences the MRPs on the surface of the 
epithelium, we then examined the virulence factors that influence HXA3-dependent PMN 
transmigration. Our observations highlighted that virulence factors influencing 
transepithelial PMN migration in general also appear to influence MRP2 translocation, 
such that there appears to be a direct correlation between MRP2 increase on the apical 
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surface of the epithelium and PMN migration. There are likely a number of virulence 
factors that induce MPR2 translocation and HXA3 production. We identified that PMN 
migration and MRP2 increases are dependent on at least PLY presence and hydrogen 
peroxide production. There is at least a third factor produced by live bacteria that induces 
this effect, as purified PLY and hydrogen peroxide, alone or together, were insufficient to 
induce PMN migration in our model. These virulence factors appear to signal through 
calcium influx and only certain types of intracellular calcium increases facilitate PMN 
migration and MRP2 apical localization.  
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Chapter II 
Transporters MRP1 and MRP2 regulate opposing inflammatory signals to control 
transepithelial neutrophil migration during Streptococcus pneumoniae lung infection 
2.1 Introduction 
Despite the availability of vaccines, antibiotics, and improved hygienic 
advancements, bacterial pneumonia remains a demanding worldwide medical challenge. 
The Centers for Disease Control and Prevention (CDC) estimate that Streptococcus 
pneumoniae (pneumococcus, S. pneumoniae), the most common bacteria associated with 
community-acquired pneumonia, causes ~400,000 pneumonia cases in the United States, 
and leads to ~35,000 deaths annually. 30% of those presenting with pneumococcal 
pneumonia develop bacteremia, a condition with mortality rates close to 20% (56, 74).  
A hallmark of pneumonia pathophysiology is the recruitment of 
polymorphonuclear cells (PMNs, or neutrophils) to the pulmonary lumen via 
extravasation and trans-epithelial transcytosis. Although PMN recruitment serves initially 
to clear invading bacteria, it also contributes directly to lung injury and pulmonary 
dysfunction (75-77). Studies have indicated that transepithelial PMN migration can 
actually mediate bacterial blood infiltration (19, 72, 73, 78, 79).  
To better understand mechanisms regulating PMN influx during pneumococcal 
infection, we previously examined host mediators of S. pneumoniae-induced PMN 
migration. Transepithelial leukocyte migration during pneumococcal infection required 
the lipid chemoattractant hepoxilin A3 (HXA3), an eicosanoid synthesized from 
arachidonic acid via 12-lipoxygenase (LOX) and secreted by lung epithelial cells (19). 
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Pharmacologic inhibition or genetic ablation of 12-LOX profoundly decreased PMN 
influx into the lungs of S. pneumoniae–infected mice and resulted in both uniform 
survival and reduced bacteremia during an otherwise lethal pulmonary challenge (19). 
Thus, 12-LOX-dependent production of HXA3 and subsequent PMN transepithelial 
migration appears to be required for high-level bacteremia.  
Most information regarding HXA3-induced PMN emigration is derived from 
studies involving intestinal Gram-negative bacterial infection (4, 11, 12, 80). At the 
intestinal surface, HXA3 apical epithelial secretion requires the ATP-Binding Cassette 
(ABC) Transporter multi-drug resistance associated protein 2 (MRP2; also known as 
ABCC2 or c-MOAT) to establish a chemotactic gradient targeting PMNs to sites of 
inflammation (4, 13). Although ABC transporters were originally identified as 
contributors to multi-drug resistance due to their capacity to extrude cytotoxic drugs, 
emerging reports suggest that they play roles in host defense and immune regulation (27, 
31, 35, 52, 81-83). To date, few studies have identified ABC transporters that mediate 
proinflammatory activity in the lung during bacterial infection. 
Herein, we demonstrate that ABC transporters MRP1 and MRP2 are diametrically 
expressed at the apical epithelial surface and actively efflux substrates that control PMN 
migration. Characterizing this relationship, MRP1 effluxes substrates that suppress PMN 
transmigration; MRP1 apical expression greatly diminishes upon S. pneumoniae 
infection. In contrast, MRP2 becomes highly enriched on the epithelial apical surface 
during pneumococcal infection and promotes PMN migration. Overall, these findings 
reveal a paradigm that epithelial cells at the lung mucosal surface act as critical sensors 
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that can determine when to initiate PMN transmigration in response to a pro-
inflammatory stimulus such as S. pneumoniae, and when to maintain a non-inflammatory 
state.  
 
2.2 Results 
 Survey of MRP expression patterns during S. pneumoniae infection 
To study inflammatory responses during infection with S. pneumoniae we have 
established an in vitro model of PMN migration using polarized monolayers of NCI-
H292 cells (H292) (84-86). We used this model to examine the profiles of MRPs that 
differ in mRNA or protein expression during S. pneumoniae infection. Whether analyzing 
whole cell protein or mRNA (Figure 2.1), little change was observed. Of note, MRP1 
decreased slightly during infection at both the mRNA and protein level. No other values 
reached 10% difference among MRP2, MRP4, or MRP5. MRP3 and P-glycoprotein were 
undetectable at basal state and during infection at the protein or mRNA level (data not 
shown).  
 
MRP1 and MRP2 show inverse patterns of expression during Streptococcus 
pneumoniae infection 
Though there were few changes observed in mRNA and protein levels, it is 
documented that MRPs undergo critical post-translational modification that affect their 
subcellular localization (26, 87). HXA3 efflux draws PMNs to the site of infection, in this 
case to the epithelial cell apical surface. To that end, we sought to specifically examine  
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Figure 2.1. MRP inquiry during infection 
NCI-H292 cells were infected with Streptococcus pneumoniae and MRP profiles 
were initially generated by 2 different techniques: protein western blots and mRNA RT-
PCR quantification. (A) MRP1, 2, 3, 4, 5, and P-gp were investigated for possible 
changes upon infection with Streptococcus pneumoniae via western blot which showed 
slight reduction in MRP1 but no other strong changes. Shown is a representative blot 
from 3 separate experiments (B) Densitometry of western blots of n=3. Protein of interest 
was normalized to loading control (GAPDH) and fold changes comparing the infected 
samples to uninfected buffer samples were calculated. (C) RT-PCR revealed a slight 
reduction in MRP1 and slight increases in MRP2 and MRP5 during pneumococcal 
infection. P-gp and MRP3 were not detectable by any of these methods.  
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changes in apical localization of our chosen proteins. We, therefore, selectively labeled 
the apical surface of infected epithelial surfaces with biotin and compared labeled 
proteins in infected and uninfected surfaces.  
Biotinylated apical MRP1 drastically decreased after infection with S. 
pneumoniae, while apical MRP2 increased (Fig. 2.2 A and B). In comparison, surface-
expressed MRP4 and MRP5 did not change (Fig. 2.2 A and B). Using 
immunofluorescence microscopy, we confirmed that pneumococcal infection induced 
localized decreases in MRP1 and reciprocal increases in MRP2 (Fig. 2.2 C and D). 
Importantly, we observed no change in MRP4 or MRP5 surface localization via 
immunofluorescence following pneumococcal infection. Based on these data, we focused 
our studies on potential modulation of MRP1 and MRP2.  
To examine whether in vitro observations correlated to changes in in vivo MRP 
localization, C57BL/6J mice were infected with 2.5x105 CFU of S. pneumoniae or mock-
infected with PBS alone. Two days post-infection, mice were sacrificed. Lungs were 
excised, sectioned, and probed to detect MRP1, MRP2, MRP4, and MRP5 via 
immunofluorescence (Fig. 2.3). Similar to our in vitro data, we saw decreases in the 
MRP1 signal and increases in MRP2 during pneumococcal infection. No such changes 
were observed with MRP4 or MRP5, pointing to a consistency in MRP modulation in 
both cell lines and the mouse (Fig. 2.3 A and B). 
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Figure 2.2. MRP1 protein on the apical surface reduces during infection with 
Streptococcus pneumoniae while MRP2 increases 
The apical surface examination of mock-infected (Buffer) or TIGR4-infected (S. 
pneumoniae) polarized H292 cells. Cells were treated with HBSS (Buffer) or infected (S. 
pneumoniae), washed, and allowed to rest at 37 degrees for 1 hour post-infection. (A) 
Apical surfaces were then labeled with biotin and lysed. Samples were normalized to 
protein content against a BSA standard, exposed to streptavidin beads, and subjected to 
an SDS-PAGE gel. Blots were probed with primary antibodies for the selected proteins. 
Shown is a representative western blot of apical biotinylation probing MRP expression. 
(B) Densitometry of summated western blot samples, across multiple experiments. 
Statistics calculated using student’s T-test as compared with MRP4 or MRP5, n=3. (C) 
Buffer treated or infected cells were fixed and stained for MRP2 and F-actin. 
Immunofluorescence cross-section Z-stack images of F-actin were utilized to identify 
cellular borders and apical surface (green). The corresponding region of MRP2-stained Z-
stack (red) was marked for the particular region of interest (white boxes) and calculated 
for the total apical coverage using ImageJ.  (D) The calculated percentage of the area 
taken up by the indicated MRPs in (C) via calculations completed in ImageJ (see 
Materials and Methods). P-value calculated using student t-test comparing uninfected and 
infected percentages for the given protein (n=8). Quantification samples for biotinylation 
and immunofluorescence were taken from at least 2 separate infections with similar 
results. 
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Figure 2.3. S. pneumoniae infection reduces MRP1 and increases MRP2 upon 
pulmonary infection in mice 
Mice were infected via an intratracheal route with S. pneumoniae and sacrificed 2 days 
post-infection. Lungs were excised, re-inflated, sectioned, and stained for MRP1, MRP2, 
MRP4, or MRP5. (A) Shown are representative images from 3 different experiments. 
Arrows indicate points of interest. In particular, areas of similar density in MRP1-stained 
lungs appear to have reduced expression in infected lungs as compared to uninfected 
lungs (arrow). MRP2 staining appears to increase significantly on the cell periphery 
during infection as compared to mock-infected lungs (arrow). No such increases or 
decreases are observed in MRP4 and MRP5. (B) Quantification of staining. Antibody 
staining was quantified and normalized to surface area (measured by F-actin, not shown). 
Shown are the fold differences of signal: surface area for each given antibody comparing 
infected (S. pneumoniae) to uninfected (Buffer) animals. Values are expressed as fold 
increase or decrease to uninfected samples.  
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MRP2 controls PMN transepithelial migration    
 Given that MRP2 controls aspects of PMN transcytosis in intestinal epithelium 
(13), we sought to examine MRP2s ability to drive pro-inflammatory events in the 
context of S. pneumoniae infection. We previously showed that PMN transmigration into 
lung airways during pneumococcal infection required HXA3 (19). We also demonstrated 
that MRP2 upregulates during intestinal inflammation and that inhibition of MRP2 
function suppresses PMN migration (13). It has not been shown, however, that MRP2 
location or activity is affected by infection by Gram-positive bacteria, such as S. 
pneumoniae. Based upon these previous findings, we examined whether pharmacological 
inhibition of MRP2 suppresses PMN transepithelial migration across pulmonary 
epithelium during pneumococcal infection.  
To inhibit MRP2, cells were treated with Probenecid, a MRP2 inhibitor (13, 88-
90). In vivo Probenecid is relatively well tolerated with death occurring in mice that 
received 1600 mg/kg (91). It is possible for Probenecid to affect other transporters, but 
more often these transporters need higher concentrations than that which is efficient to 
inhibit MRP2 (29, 81, 92, 93). In addition, Probenecid has been shown to have some 
effects in inhibiting MRP1 (94); however, biotinylation data in Fig. 1 and 2 would 
indicate that MRP1 is already reduced during infection. Any effects inhibiting MRP1 
would likely exacerbate, rather than curtail, PMN recruitment during infection. This idea 
will also be explored in more detail later in the manuscript. 
Cells were treated 1 hour pre-infection with Probenecid and then subjected to 
infection and a PMN-migration assay. Probenecid treatment had no effect on the basal 
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PMN migration across uninfected cells but suppressed PMN transmigration across 
infected H292 monolayers by ~3-fold (p<0.05) compared to mock-treated controls (Fig. 
2.4A). However, when we used a different PMN chemoattractant that acts independently 
of the HXA3 pathway, formyl-methionyl-leucyl-phenylalanine (fMLP) (95, 96), we failed 
to observe any Probenecid-related reduction in PMN migration (Fig. 2.4B).To ensure the 
PMN transmigration was not due to pneumococcal-mediated epithelial cell apoptosis, we 
performed Annexin V staining (Fig. 2.4C) and found no significant increase in apoptosis 
during infection, consistent with previous reports (97). 
 
MRP2 inhibition mitigates pulmonary PMN infiltration and bacteremia following 
lung challenge with S. pneumoniae. 
S. pneumoniae intratracheal infection of C57BL/6J mice initially causes 
pneumonia, leads to bacteremia, and, ultimately, septicemia that causes death (98). As 
shown previously, reduced PMN migration can diminish bacteremia and improve 
survivability of pneumococcal-infected mice (19, 72, 73). With the knowledge that 
MRP2 inhibition diminishes PMN migration in vitro, we sought to test whether MRP2 
function had subsequent impact on disease in our murine infection model, especially in 
the context of PMN transmigration.  
Four sets of experiments were conducted: all involved mice that were pre-treated 
with either PBS or Probenecid at 1mg/kg delivered via the trachea to inhibit MRP2 
function. Previous studies in this specific model have indicated that maximal PMN 
recruitment occurs between 18- and 24-hours post-infection (73); therefore, two sets of 
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mice were sacrificed at either 24- or 48-hours post infection to examine the leukocytes 
entering the lung via Bronchial-Alveolar Lavage (BAL) collection (see Materials and 
Methods). The third set was sacrificed 2 days post-infection to test for bacteremia, and 
total lung burden. The fourth set was monitored for morbidity that would require sacrifice 
as dictated by our SOP (see Materials and Methods).  
Upon examining the contents of BAL fluid, we noted that Probenecid treatment 
consistently reduced the number of neutrophils on the first day post-infection by ~35% 
(Fig. 2.5A). This trend continued through 48-hours post-infection and the combined 
values of 24- and 48-hour PMN infiltration showed significant differences as calculated 
using two-way ANOVA. When measuring expression of pro- and anti-inflammatory 
cytokines from the BAL, we noted that there appeared to be no substantial differences 
between probenecid-treated and mock-treated animals in any of the measured 
inflammatory cytokines at the times mentioned, with exception to a reduction in IL-10 in 
probenecid treated mice at 24-hours post-infection (Fig. 2.6). We don’t believe that this is 
a substantial physiological difference as reductions or eliminations of IL-10 in S. 
pneumoniae infected mice generally lead to a larger infiltration of PMNs, not fewer 
((99)). No other significant differences in T-cells, macrophages, or dendritic cells were 
observed (Fig. 2.7). Despite the reduction in PMNs, no differences were observed in 
pulmonary bacterial burden 48-hours post-infection (sacrificed whether exhibiting 
morbidity or active and healthy, Fig. 2.5 B) or upon death during survival experiments 
(Fig. 2.7D).  
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Figure 2.4. MRP2 inhibition via probenecid reduces PMN migration across 
polarized pulmonary epithelial cells which is not dependent on apoptosis 
Polarized NCI-H292 cells on filter membranes were incubated with 100µM of the MRP2 
inhibitor Probenecid or mock-treated for 1 hour with PBS before (A) apical infection 
with S. pneumoniae at 10 MOI or (B) the HXA3-independent bacterial product formyl-
methionyl-leucyl-phenylalanine (fMLP). For both (A) and (B), mock-infected/treated 
cells were exposed to HBSS for the treatment time- period and basolateral-to-apical 
migration of PMNs was quantified with a myeloperoxidase assay against a standard 
number of PMNs (see Materials and Methods). Shown is one representative experiment 
from at least 3 experiments performed. Statistics completed using students T-test.  
(C) H292 cells were treated with HBSS, wild-type TIGR4 S. pneumoniae, or the 
cytotoxic compound staurosporine at 1 µM. There was no significant increase in Annexin 
V staining in infected cells (black) when compared to uninfected buffer control cells 
(white).  
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In line with previously mentioned data supporting that reduction of infiltrating 
PMNs reduces bacteremia, probenecid treated animals showed fewer mice exhibiting 
bacteremia and ~10-fold lower CFU in the blood during the first 24-hours as compared to 
PBS-treated mice (Fig. 2.5 C). This trend continued in the 48-hour time-point though did 
not reach statistical significance. The resulting survival curves showed probenecid 
treatment improved survival by 30-40% consistently (Fig. 2.5 D). Therefore, MRP2 
inhibition via Probenecid treatments was found to be effective at limiting PMN 
infiltration to the lung 24 h post-infection, corresponding to a reduction in bacteremia and 
increased survival. This is not to say, however, that we seek to use Probenecid as a 
treatment for S. pneumoniae infection or that it should be given prophylactically. We 
merely are using Probenecid to highlight that MRP2 is an interesting molecule for further 
research/therapeutic targeting.  
 
MRP2 and MRP1 promote the secretion of proinflammatory and anti-inflammatory 
lipids, respectively. 
To better understand how MRP1 or MRP2 function could impact pneumococcal-
induced PMNs, we generated H292 cell lines constitutively expressing shRNAs targeting 
MRP1 or MRP2 expression (Fig. 2.8). Because it is known that MRP2 is able to efflux 
the pro-inflammatory molecule HXA3 in the intestines (13), we hypothesized limiting 
MRP2 expression would reduce the amount of HXA3 effluxed during pneumococcal 
infection. As HXA3 is an eicosanoid, we began by assessing the properties of 
hydrophobic material(s) enriched from apical secretions of S. pneumoniae-infected 
		
44	
 
 
  
Wi
th 
Ba
cte
rem
ia
W/
O 
Ba
cte
rem
ia
1×102
1×103
1×104
1×105
1×106
1×107
1×108
1×109
CF
U/
Lu
ng
Lungs
PBS
Probenecid
Fig. 2.5 
Bacteremia 
105 
106 
107 
108 
104 
103 
102 
C
FU
/L
un
g 
+ - 
Probenecid 
PBS 
109 
24 48
1000
10000
Hours PI
N
um
be
r o
f P
M
N
s
Ly6G
PBS
Probenecid
1 4 
1 3 
B. 
P
M
N
s 
24 48 
Hours Post-Infection 
P <0.05 A. 
D1 D2
1×102
1×103
1×104
1×105
1×106
1×107
Days PI
CF
U/
m
L 
bl
oo
d
Tabulated Data Blood
PBS
Probenecid
P <0.005 
C
FU
/m
L 
B
lo
od
 
107 
106 
105 
104 
103 
102 
D1 D2 
C. 
0 24 48 72 96 120
0
10
20
30
40
50
60
70
80
90
100
110
Time
Pe
rc
en
t s
ur
vi
va
l
PBS
Probenecid
D. 
Hours Post-infection 
S
ur
vi
va
l P
er
ce
nt
ag
e 
P <0.05 
Probenecid 
PBS 
		
45	
Figure 2.5. MRP2 inhibition mitigates pulmonary burden and bacteremia following 
lung challenge with S. pneumoniae 
Using an in vivo model of PMN migration, we examined the results of MRP2 inhibition. 
C57/Bl6 mice were treated with either PBS or Probenecid 3 hours prior to- and 3 hours 
post-intratracheal application of 2.5x105 S. pneumoniae. Four sets of mice were infected 
in this way (A) Comparing the number of PMNs found in the lumen after isolating BAL 
after 24- and 48-hours post-infection. PMNs, identified as Ly6g-positive cells were 
quantified by flow cytometry (n=8).  (B) Overall lung burden from mice sacrificed on 
day 2. Mice were sacrificed, lungs were excised, homogenized, and total burden was 
calculated using serial dilutions (n=24 each condition). (+) Bacteremia indicates that 
mice had detectable levels of bacteria in the blood 48-hours post-infection. (-) Bacteremia 
indicates no bacteria were detectable in the blood during tail-vein bleeds (C) Bacteremia, 
as measured by tail vein bleeds, from cohort from (B) (see Materials and Methods). 
Shown are detectable events of colony formation on D1 and D2 (n=24). The dotted line 
represents the limit of detection and, as such, mice without visible bacteremia were 
represented as “100 CFU/mL”, just below this level of detection.  B and C statistical 
significance was calculated using Mann-Whitney test. (D) Presented is the 4th set of mice, 
a survival experiment. n= 16 mice per condition, statistics were calculated using Mantel-
Cox test and Gehan-Breslow-Wilcoxon test. Probenecid-treatment consistently increased 
survival by approximately 30-40% during survival experiments and often delayed 
symptoms, such as lethargy. Mouse experiments were repeated and observed to have 
similar results in at least 2 different experiments.  
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Figure 2.6. ELISA data shows no significant pro-inflammatory differences  
3 mL BAL samples from infected mice in Figure 4A (and Supplemental Figure 4 B, C, 
and D – all samples are from the same 8 mice). Both PBS mock-treated and Probenecid-
treated mice were infected and BAL was tested for TNF (A), KC (B), the murine 
equivalent to IL-8), MIP2 (C), and IL-10 (D). No significant differences were observed 
except for IL-10, as calculated by 2-way ANOVA. Values were slightly lower than 
expected due to the elution of BAL fluid in 3mL instead of the classic 800 µL-1mL. 
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Figure 2.7. Pulmonary burden during survival experiments and in vivo granulocyte 
enumeration 
(A, B, C) Additional leukocytes identified in the BAL quantified by flow cytometry. 
These include T-cells (B, Cd3+ cells), Macrophages (C, Cd11b+/Cd45+/Ly6g- cells), and 
Dendritic cells (D, Cd11c+/Cd11b-/Ly6g- cells). Samples are from the same sample set 
as Figure 2.5A. (D) Pulmonary burden calculated using serial-dilution of lung 
homogenates during survival experiments in Figure 2.5, taken from mice that died. No 
difference in bacterial burden was observed at the end-point of survival examinations. All 
statistical significances were calculated using Mann-Whitney test (for individual time-
points) as well as 2-way ANOVA (combined time-points). 
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Figure 2.8. shRNA constructs result in knockdown of MRP1 and MRP2 expression 
H292 cells were transfected with a control shRNA plasmid containing a scrambled 
construct, 1 of 3 MRP1 shRNA constructs, or 1 of 3 shRNA MRP2 constructs. Cells were 
selected under puromycin antibiotic selection and assessed via western blot. Shown is a 
representative western blot of 3 lysis events. Cultures with arrows indicate the shRNA 
pool selected for MRP1/MRP2 knockdown experiments.  
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polarized H292 cell monolayers. We used a previously described method (13) utilizing 
methanol elution of a C18 column to enrich bioactive lipid(s) following application of a 
pathogen to the apical surface of epithelial monolayer  (Fig. 2.9A). To reconstitute the 
lipid chemoattractant, the methanol-lipid solution was evaporated over a steady stream of 
compressed nitrogen and resuspended with HBSS. The isolated lipid-HBSS was then 
applied to the apical surface of naïve H292 cells during a PMN transmigration assay. As 
expected, resuspended lipid-isolates from uninfected cells yielded no PMN migration, 
indicating there is no chemoattractant produced by the cells without infection (Fig. 2.9B). 
When we applied resuspended lipid chemoattractant isolated from infected cells to the 
apical surface of H292 cells during a PMN transmigration assay, we induced PMN 
migration (Fig. 2.9B). Extracts isolated from H292 monolayers with reduced MRP2 
expression were less effective at inducing PMN transmigration than H292 cells 
transfected with a scrambled shRNA sequence, in a manner similar to data reported in 
Figure 3 for Probenecid, indicating a direct correlation between MRP2 expression and 
PMN migration (Fig. 2.9B).  
On the basis of reduced MRP1 surface expression during pneumococcal infection, 
we further hypothesized that MRP1 is involved in an anti-inflammatory cascade that 
suppresses PMN transepithelial migration. To test this theory, we once again resuspended 
the isolated lipid chemoattractant from Figure 2.9A to conduct a PMN migration assay. 
Instead of resuspending the chemoattractant with conventional HBSS, we conditioned 
HBSS with apical supernatants from either scrambled-control or MRP1-deficient knock-
down cells. We expected MRP1 to secrete a molecule or molecules during basal, 
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uninflamed states (when MRP1 was highest) that would directly inhibit PMN 
transmigration. Media conditioned with MRP1 competent cells, then, would reduce PMN 
migration. Media conditioned with apical supernatants from MRP1 KD cells would show 
no such inhibition.   
When examining the results of conditioning the media with uninfected apical 
secretions, the resulting PMN migration with normal HBSS without isolated lipids 
induced no PMN migration, as expected (Fig. 2.9C). Lipids resuspended with media 
conditioned with wild-type, MRP1-competent cells inhibited PMN migration when 
compared to lipids resuspended with unconditioned HBSS (Fig. 2.9C). When conducting 
a PMN migration with lipids conditioned with MRP1-deficient cells, we lost the 
inhibition observed with cells that had intact MRP1 expression (Fig. 2.9C). When we 
again used fMLP to examine the HXA3 dependency, we again failed to observe a 
reduction in PMN migration (Fig. 2.9D). In addition, we saw no changes in TNF, IL8, 
CXCL2, or IL-10 signaling in MRP1 knockdown cells either prior-to or post-infection as 
measured by ELISA (Fig. 2.10). Thus, it appears that MRP1 inhibits HXA3-specific PMN 
migration in vitro and by reducing MRP1 expression, we diminished the inhibition on the 
PMN migration that we observed with wild-type cells.  
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Figure 2.9. MRP2 and MRP1 promote the secretion of proinflammatory lipids and 
anti-inflammatory molecules, respectively  
(A) Pro-inflammatory lipids were isolated from apical supernatants of pneumococcus-
infected H292 monolayers. HBSS subjected to the apical surface of pneumococcal-
infected H292 were enriched on C-18 columns, which retain the pro-inflammatory lipids, 
and eluted in methanol for storage (see Materials and Methods). Yellow triangles 
represent proinflammatory lipids. (B) Lipids from MRP2-competent (Scrambled-control) 
and MRP2-deficient (MRP2 KD) cells were enriched and eluted with methanol. This 
methanol/lipid solution was evaporated under a constant stream of nitrogen and 
resuspended in HBSS to be used as PMN chemoattractant during a PMN migration assay 
through a monolayer of naïve wild-type H292 cells.  
 (C) Proinflammatory lipids isolated from wild-type cells infected with S. pneumoniae 
from (A) were resuspended with either unconditioned media (Unconditioned media), 
conditioned media from MRP1-competent scrambled-control cells (Wild-type 
conditioned media), or conditioned media from MRP1-knockdown cells (MRP1 KD 
conditioned media) and applied to the apical chamber of naïve cells to act as a 
chemoattractant during a PMN migration assay. HBSS without any lipid acted as 
negative control (Buffer Negative control). (D) MRP1-conditioned media failed to inhibit 
HXA3-independent PMN-migration produced using formyl-methionyl-leucyl-
phenylalanine (fMLP). NS represents “No significance” when examining student’s T-
test.  
  
		
53	
  
  
Figure 2.10. Neither MRP1 knockdown nor probenecid treatment significantly 
changes the ELISA profile of tissue culture cells within 1 hour of infection 
Wild-type (WT, Black circles), Scrambled-control (SC, Open circles), MRP1 knockdown 
(MRP1, Triangles), and probenecid-treated (Prob, Grey squares) H292 cells were 
subjected to ELISA sample collection. HBSS+ was incubated for 1 hour post-infection in 
either mock-treated cells (Buffer) or Streptococcus pneumoniae-infected cells (S. 
pneumoniae) and collected from the apical surface for ELISA. No significant changes 
were observed in TNF (A), IL8 (B), CXCL2 (C), or IL10 (D) when comparing 
Scrambled-control cells to MRP1 knockdown cells or wild-type to any of the other 
conditions. Shown are 2 separate runs pooled together and experiments were repeated 
with similar results.  
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2.3 Discussion 
Lower respiratory tract infections are among the leading causes of death 
worldwide, and S. pneumoniae remains the deadliest bacterial agent causing this 
affliction. Infection of the lung with S. pneumoniae induces a variety of inflammatory 
responses, the pathological hallmark of which is massive influx of PMNs. In this role, 
PMNs are signaled to navigate to the site of infection and are charged with the task of 
pathogen eradication. Outright neutropenia or elimination of PMN activity at this step is 
detrimental to the host, as a full adaptive immune reaction has not had time to activate 
and the bacteria are unabated. However, unchecked, PMN recruitment lacking resolution 
culminates in massive tissue destruction, and ultimately lung failure. Thus, one of the key 
challenges in treating lung inflammation lies in attenuating the inappropriate influx of 
PMN without compromising the ability of the patient to fight normal infections. We 
envisage that a better understanding of the mechanisms underlying the regulation of PMN 
influx during pneumococcal infection is essential to designing improved therapies that 
dampen detrimental lung inflammation. This is a logical approach for S. pneumoniae, as 
this bacterium is encapsulated, countering PMN as a critical host defense mechanism. 
Thus, the cost of host tissue damage as a result of PMN infiltration of the airway 
epithelium during pneumococcal infection significantly outweighs any benefit PMNs 
may have in defense of this particular infection.  
Although several studies have probed aspects of PMN recruitment to the airspace 
using a range of in vitro and in vivo models, many molecules mediating innate immune 
responses during pneumococcal pneumonia infection are redundant and/or dispensable 
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for PMN recruitment (100-107). As shown herein, we have uncovered a system of 
checks-and-balances in which eukaryotic ABC efflux transporters facilitate the 
coordination of PMN transepithelial migration across lung epithelia in response to 
pneumococcal infection. We have found that expression of the efflux transporter MRP1 
on the apical surface of the lung epithelium is high in a normal basal state. The action of 
MRP1 at this site is to maintain homeostasis through efflux of immunosuppressive 
bioactive molecules that we have termed L- AMEND (Lung-
Activity Modulating Epithelial-Neutrophil Discourse). Under the same homeostatic state, 
expression of another efflux pump, MRP2 is quite low, reinforcing the anti-inflammatory 
arm of this pathway. However, upon introduction of a foreign invader, such as S. 
pneumoniae, expression of MRP1 is decreased, reducing the effective concentration of 
anti-inflammatory molecules at the site of infection. MRP1 reduction is accompanied by 
an increase in the apical expression of MRP2, which facilitates the efflux of the 
proinflammatory eicosanoid, hepoxilin A3; a potent PMN chemoattractant that in turn, 
attracts PMNs to the site of infection/injury (Fig. 2.11). 
Critically, while it is known that HXA3 is necessary in pneumococcal-induced 
PMN translocation (19) and lung infection (18), no studies have ever shown the link 
between MRP2-dependent HXA3 efflux and Gram-positive bacteria, highlighting the 
conservative nature of the HXA3/MRP2 axis. Additionally, we found that blockade of 
MRP2 by Probenecid during S. pneumoniae infection profoundly decreased PMN influx 
into the lungs of infected mice and, in turn, reduced the extent of systemic bacteremia. 
Our discovery that MRP1 effluxes L-AMEND, which suppresses PMN migration, 
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Figure 2.11. Epithelial MRPs assist in controlling pro- and anti-inflammatory states    
Shown by this work, lung epithelium expresses high amounts of MRP1 and low amounts 
of MRP2 at basal (uninfected) states. MRP1 effluxes molecules with anti-inflammatory 
activity, here termed L-AMEND, which acts to suppress PMN migration. During 
infection with Streptococcus pneumoniae MRP1 is reduced and MRP2 increases on the 
apical surface of the epithelium. MRP2 mediates release of the pro-inflammatory 
molecule Hepoxilin A3 (HXA3), which creates a chemotactic gradient to draw PMNs to 
the site of infection. By both reducing MRP1 and increasing MRP2, the epithelium works 
to maximize the transepithelial PMN migration; however, this PMN migration also 
disrupts epithelial tight junctions and can lead to infiltration of the intruding S. 
pneumoniae.  
MRP1 
L-AMEND L-AMEND 
L-AMEND 
HXA3 
HXA3 
S. pneumoniae 
Basal State Infection 
Epithelium 
Fig. 2.11. 
Apical surface 
Basolateral surface 
MRP2 
HXA3 
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provides two potential and independent treatments strategies to reduce PMN migration 
and, thus, limit development of bacteremia: apical presentation of exogenous L-AMEND 
or local inhibition of MRP2. It remains to be seen as to what, exactly, makes up the 
components of the L-AMEND. When examining efflux supernatants from MRP1 
knockdown cells or probenecid treated cells, we saw no discernable differences in the 
conditioned milieu as examined by ELISA (Fig 2.10).  
We chose an intratracheal administration of bacteria in our studies to highlight the 
transition from lung- to blood-infection. One of the major focuses of this study was to 
examine whether MRP2 inhibition would augment PMN infiltration to the lungs during 
infection. Secondary to this, we sought to confirm that the PMN infiltration correlated 
with the development of bacteremia over the course of infection. Intratracheal infection 
seemed the most direct route to test this, bypassing any bottleneck in intranasal 
application, and guaranteeing bacteria enter the lung. Histology revealed that lung 
pathology does not appear different between Probenecid-treated and PBS-treated animals 
(Fig. 2.12A), seeming to indicate that all of the mice had equal opportunity to develop 
bacteremia. Because the infection is delivered almost directly to the lung in a bolus, it 
seemed reasonable that both cohorts exhibited similar lung pathology – the major 
difference between the two seems to be the induction of bacteremia and PMN infiltration, 
not the lung infection by itself. To that extent, one particular question that seemed 
interesting but unexplored was whether there might be fewer permissible passages of 
PMN entry or if fewer PMNs might be coming through in lesser numbers in Probenecid 
treated samples. The former seems more likely as HXA3 has been demonstrated to be 
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critical in initial passage of PMNs but doesn’t control the continued passage once the 
initial PMN passageway has been breached (108). In Probenecid treated mice, therefore, 
MRP2 blockade would lead to fewer paracellular openings and only slightly fewer PMNs 
but a significant reduction in the number of breakages by which bacteria pass through. 
While our studies are the first to identify a push/pull interaction between MRP1 
and MRP2 in PMN migration, there is another study examining MRP1 that presents an 
interesting paradox. Schultz et al. previously reported global Mrp1 knockout mice were 
protected during intranasal pneumococcal (serotype 3) infection in a leukotriene B4 
(LTB4)-dependent manner whereas wild-type littermates succumb to infection (49). At 48 
h post-infection, extracellular leukotriene C4 (LTC4) in Mrp1-/- BALF was lower than in 
wild-type mice. Intracellular LTC4, understandably, was found to be higher, leading to 
the conclusion that release of LTC4 was inhibited by the elimination of murine 
MRP1(49). In a separate study, intracellular LTC4 retention was suggested to be 
cytotoxic (35). Because PMNs express MRP1, a global knockout would yield MRP1-
deficient PMNs. This could lead to PMN apoptosis and reduced numbers, exactly the 
observation in the Schultz study 48 h post-infection. With this explanation, it would 
appear that the previously reported Mrp1 knockout data does not refute our stated results. 
Additionally, this is yet another communication reinforcing that fewer PMNs responding 
to bacterial infection actually can improve survival in S. pneumoniae infection. 
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Figure 2.12. Histological examination shows little difference between Probenecid 
and PBS treatment during infection 
(A) Mouse lungs were excised, sectioned, and underwent H&E staining. Slides were 
scored blindly. Although pathology scores worsened when comparing 24 and 48 hours 
post-infection, no statistically significant differences were observed between Probenecid- 
and PBS-treated animals. Prob abbreviation indicates 1 mg/kg intratracheal Probenecid 
treatment, Sp indicates animals were infected with Streptococcus pneumoniae. Lungs 
were excised either 24 (24 PI) or 48 (48 PI) hours post-infection. PBS and Probenecid 
treated animals without infection were scored and grouped whether sacrificed 24- or 48-
hours post mock-infection. n=4 for infected animals, n=3 for PBS- and Probenecid-
treated mock-infected animals for each time point. (B) H292 cells with control constructs, 
MRP1 shRNA, or MRP2 shRNA underwent staining for apoptosis post-infection. There 
were no significant increases in apoptosis between scrambled control and knockdown 
cells during the staining procedure. P-values calculated using students T-test.  
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There remains the possibility that epithelial-derived LTB4 could influence PMN 
migration, however it has been shown that LTB4 released by cells during in vitro PMN 
transmigration is almost exclusively PMN-derived (108), eliminating the possibility that 
the epithelium is coordinating PMN migration with LTB4 in our MRP1 knock-down 
studies. To ensure that our infected epithelium do not undergo LTC4-induced apoptosis, 
we tested Annexin V staining post-infection in MRP1-deficient epithelium when 
compared to control cells (Fig 2.12B), and found no differences, indicating that any 
increases in PMN migration associated with MRP1 deficiency is not caused by epithelial 
cytotoxicity.  
Our hypothesis that MRP1/L-AMEND dictates an anti-inflammatory state while 
MRP2/HXA3 assists in pro-inflammatory activity incorporates the concept that epithelial 
cells (through regulation of ABC efflux transporters) act as sensors that integrate signals 
to determine when and to what level to incite PMN transmigration (Fig. 2.11). Thus, a 
steady state, non-inflamed condition is established that limits inappropriate inflammatory 
responses but is poised to respond to pathogens, such as S. pneumoniae. Although this 
PMN response is critical in controlling the infection at hand, prolonged PMN activation 
also has deleterious effects on health, highlighting a cost-benefit relationship for the host. 
These findings regarding the nature of this anti-/pro-inflammatory balance could provide 
clinical targets for therapeutic control of dysregulated respiratory innate inflammatory 
responses that ultimately allow for containment of the infection but simultaneously 
dampen detrimental lung inflammation. 
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2.4 Materials and Methods 
Cell culture 
The human mucoepidermoid pulmonary cell line, NCI-H292 (H292), was 
cultured with RPMI (GIBCO #11875-093) supplemented with 10% FCS and subcultured 
using 0.05% Trypsin-EDTA (GIBCO #25300-054). Transmigration cells were prepared 
on 24-well inverted semi-permeable membranes (Costar #3421) and grown to 
confluency. Cells for RNA/protein assays were grown to confluency on 6-well 
membranes. MRP1, MRP2, and scrambled-control knockdown cell lines were developed 
by chromosomal integration of pLOK.1 shRNA constructs in wildtype H292 cells, 
selected with puromycin, and confirmed by western blot.  
 
Bacteria 
Streptococcus pneumoniae serotype 4 (TIGR4) was provided by Drs. John Leong 
and Andrew Camilli (Tufts School of Medicine). Bacteria were streaked overnight on 5% 
sheep-blood Tryptic Soy Agar (Northeast Laboratory Services #p-1100) and grown at 
37°C, 5% CO2 for 14-20 hours. On the day of infection, bacteria were resuspended with 
Todd-Hewitt-Yeast media and supplemented with oxyrase (#OB-0100, 5uL/mL culture). 
Cultures grew to ~5x108 CFU/mL. In vitro infections were diluted in Hanks Balanced 
Salt Solution (HBSS, GIBCO #14025-092). Mouse infection solutions were resuspended 
using filter-sterilized Phosphate Buffered Saline (PBS).  
 
RT-PCR 
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Confluent H292 on 6-well membranes were rinsed with HBSS and infected 
apically with TIGR4 (~10 MOI) for 1 hour. Cells were washed with HBSS and RNA was 
collected using Qiagen RNeasy kits (Qiagen #74106) following suggested protocol. 
cDNA was obtained using Qiagen QuantiTect following manufacturers instructions. RT-
PCR data was obtained using SybrGreen with custom primers for each transporter (in 
triplicate) normalized to expression of GAPDH.  
 
Transmigration 
Transmigrations were conducted as previously described (3) using H292 cells. 
Probenecid (Sigma #P8761-25G) was diluted in HBSS before being solubilized with 
NaOH and brought to pH 7.4 with HCl. Probenecid treatment at 100 µM was completed 
1 hour prior to infection. H292s were infected apically with wild-type TIGR4 (~10 MOI) 
for 1 hour and washed. Human neutrophils were isolated from healthy donors using 
methods previously published (13). Freshly isolated neutrophils were applied to the 
basolateral chamber of infected membranes and allowed to migrate. Neutrophil migration 
was quantified using a myeloperoxidase assay. N-Formyl-methionyl-leucyl-
phenylalanine (fMLP) was purchased from MP Bioscience (Cat# 151170) and used at a 
final concentration of ~150 nM during PMN migrations. 
 
Biotinylation 
H292 cells were grown on 6-well transmembranes to confluency, rinsed with 
HBSS, and infected with TIGR4 (~10 MOI) apically. Cells were washed and biotinylated 
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as previously described (109, 110). Cells were lysed and passed through 26½ -gauge 
needles, spun, and applied to streptavidin beads (Thermo Fisher #20347) or saved in 
tricine sample buffer (recipe from Bio-rad 161-0739). Biotinylated-bead samples were 
incubated at 4°C overnight, washed, incubated at 40°C for 20 mins in tricine sample 
buffer, then run on 4-20% TGX protein gel. Proteins were transferred on to nitrocellulose 
membranes, blocked, and incubated with the indicated antibodies: MRP1 (ABCAM 
ab24102), MRP2 (ABCAM ab3373), MRP3 (ABCAM ab3375), MRP4 (ABCAM 
ab56675), MRP5 (ABCAM ab77369), P (EMDMilipore 517310), GAPDH 
(EMDMilipore MAB374). HRP-conjugated secondary antibodies were used to visualize 
western blots. 
 
Mouse infections 
C57BL/6J mice were purchased from Jackson Laboratories. For lung 
immunofluorescence images, mice were anesthetized with isoflurane and mock-infected 
with PBS or infected with 50µL TIGR4 intratracheally (~2.5x105 CFU/infection). 
Infections progressed for 48 hours and mice were sacrificed. Lungs were re-inflated with 
1mL 1:1 PBS/OCT mixture, frozen in OCT, and processed. For histological studies, mice 
were sacrificed and lungs were re-inflated and fixed with 10%formalin/PBS for a 
minimum of 24 hours. Lungs were processed, sectioned, and haemotoxylin and eosin 
(H&E) stained. Dr. Jerrold Turner, M.D., and associates scored pathology. CFU was 
calculated via lung homogenization and serial dilution plating. 
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For probenecid studies, mice were pretreated 3 hours prior to infection with 
1mg/kg Probenecid, diluted in PBS, applied intratracheally. Mice were mock-infected 
with PBS or infected with 2.5x105 CFU TIGR4, after which Probenecid was administered 
3 hours post-infection. For bacteremia, 10 µL of blood was removed via tail vein lancet 
and diluted in anticoagulant for serial plating. ELISA samples and leukocyte panels were 
generated using a modified BALF isolation protocol (111). 1mL samples of PBS were 
applied to mouse lung via the trachea 3 times and spun in a centrifuge at 2000RPM. 
Supernatant was frozen for ELISA experiments and cells were washed and went to FACS 
processing. Following red blood cell lysis, cells and Fc receptors (Biolegend Cat# 
101319) were blocked in PBS/0.5% FBS. Staining was achieved via incubation with 
Cd11b (Biolegend Cat#101236), Ly6G (Biolegend Cat#127618), or CD45 (Biolegend 
Cat#103130) and run on a MACSquant analyzer. Populations were analyzed via FloJo. 
ELISA kits were obtained from R&D systems (cat # DY453-05, DY452-05, DY217B-05, 
and DY410-05) and assays were completed using manufacturers instructions. 
 
For survival curves, mice were sacrificed when exhibiting 3 of the following 
within 6-hours, according to our SOP: lethargy, shivering, loss of more than 10% body 
weight, and fur ruffling. In all survival experiments, animals showed no signs of 
pathology past 96-hours of infection. Repeated experiments going to 168-hours post-
infection showed similar results. Survival curve statistics were calculated using Mantel-
Cox test as well as Gehan-Breslow-Wilcoxon test. All experiments completed with 
approval of UMASS IACUC #1905. 
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Immunofluorescence 
Immunofluorescence H292 samples were grown on inverted membranes and 
either mock-infected or infected with ~10MOI TIGR4 apically prior to fixation with 4% 
paraformaldehyde. Cells were washed, blocked with 3% BSA, and permeabilized with 
0.01% Triton-X. Samples were stained with primary antibodies MRP1 (Santa Cruz sc-
7773), MRP2 (Santa Cruz sc-5770), MRP3 (ABCAM ab3375), MRP4 (ABCAM 
ab56675), or MRP5 (ABCAM ab77369). Secondary-antibody incubations were with 
Alexa488/Phalloidin569 (Life Technologies #A12380) or Alexa568/Phalloidin488 (Life 
Technologies #A12379). Images were taken with a Leica SP-5 confocal microscope and 
calculations were completed using Image J. Images were converted to 8-bit, threshold 
was set for a given protein, and calculated for percent area in a given region of interest. 
All corresponding uninfected and infected images were infected, stained, and imaged on 
the same days as to reduce confounding factors and standardize the apical coverage 
calculations.  
Mouse lung sections were fixed with 4% paraformaldehyde, blocked with 3% 
BSA, and permeabilized with 0.01% Triton-X. Slides were incubated with the indicated 
primary antibody, washed, and incubated with 1:1000 with the above secondary 
antibodies. Increases or decreases of signal were calculated using Image J to assign an 
arbitrary signal under parameters described with H292 immunofluorescence. Fold 
differences in Figure 2B were calculated by quantifying signal for specific antibodies and 
normalizing to surface area according to phalloidin staining. These ratios were averaged 
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and the buffer average was set to a ratio of 1. All samples were then standardized to the 
buffer average for each given antibody and fold increases or decreases were reported.  
 
Lipid isolation 
H292 and MRP2 KD cells were grown and infected as in biotinylation steps. 
HBSS applied post-infection was collected, debris removed via centrifugation, and 
solution was applied to a C-18 solid phase extraction column (Supelco Cat#52604-U). 
Lipids were eluted using methanol and stored at -80°C for up to 1 month.  
To analyze activity, lipid-methanol solutions were dried under constant nitrogen 
stream and resuspended in pre-warmed HBSS. HBSS/lipid was applied to the apical 
surface of inverted naïve H292s and PMN migrations were completed as described.  
MRP1 inhibition was tested using pre-warmed HBSS applied to the apical surface 
of control or MRP1 KD cells for 5 hours, producing conditioned media. Lipid-methanol 
solutions from above were dried and resuspended with unconditioned HBSS, conditioned 
HBSS from MRP1-competent cells, or conditioned MRP1 knockdown media. Migrations 
were then conducted as described.   
Human ELISA kits were obtained from R&D systems (DY210-05, DY217B-05, 
DY276-05, and DY208-05) and assays were completed using manufacturers instructions. 
To collect samples, 6-well filter-insert plates were seeded with H292 cells and grown to 
confluency. Cells were equilibrated in pre-warmed HBSS+ and either mock-treated or 
infected with 10 MOI of Streptococcus pneumoniae on the apical surface for 1 hour. 
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Cells were then washed and 1 mL HBSS+ was placed on the apical surface for 1 hour for 
sample collection.  
 
Apoptosis 
For apoptosis, inverted H292 constructs were infected with 10 MOI TIGR4 or 
Staurosporine (Santa Cruz #sc-3510a) as a positive control for one hour. Cells were 
washed and rested at 37° in HBSS for an additional two hours. Cells were lifted using 
0.05% Trypsin-EDTA, washed, and stained with Annexin V-FITC and Propidium Iodide 
(Santa Cruz Cat#sc-4252 AK). Staining was visualized and enumerated using a 
MACSquant analyzer and FloJo. Three constructs per condition were pooled and data 
shown is the summation of 3 different infections.  
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Preface to Chapter III 
Elucidating the Streptococcus pneumoniae virulence factors that  
modulate epithelial HXA3 production and MRP2 plasma membrane enrichment  
 
Work contained in this Chapter is unpublished data detailing experiments that attempt to 
elucidate how virulence factors from S. pneumoniae induce PMN migration and influence 
MRP2 localization during epithelial cell infection.  
 
All experiments were completed by Andrew Zukauskas and significant intellectual 
contributions have been made by Andrew Zukauskas, Dr. Beth McCormick (UMASS 
Medical School), Dr. John Leong (Tufts University), Dr. Rudra Bhowmick (Oklahoma 
State University), Dr. Elsa Bou-Ghanem (Tufts University), and Dr. Walter Adams (Tufts 
University).  
As indicated in the Materials and Methods, purified cytolysins were generously donated 
by Dr. Rod Tweten (Oklahoma University) through Dr. John Leong.  
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Chapter III 
Elucidating the Streptococcus pneumoniae virulence factors that  
modulate epithelial HXA3 production and MRP2 plasma membrane enrichment  
3.1 Introduction 
In the previous chapter, we demonstrated that the ABC-transporters, Multi-drug 
Resistance associated Proteins 1 and 2 (MRP1 and MRP2), coordinate pulmonary PMN 
transepithelial migration in response to S. pneumoniae. MRP1 effluxes a molecule or 
molecules that inhibit PMN transmigration at resting state (i.e. without inflammatory 
stimuli). During infection, MRP1 reduces while MRP2 increases and effluxes the pro-
inflammatory PMN chemoattractant HXA3 (Figure 2.11). This MRP2/HXA3 effect is a 
conserved action coordinating PMN transepithelial migration to a variety of mucosal 
surfaces (i.e. lung, and gut) in response to bacteria including E. coli, Salmonella, and 
Shigella (4, 11, 12) and pulmonary infections with Pseudomonas aeruginosa. Since it 
appears that HXA3 production and efflux is a conserved innate immune signaling 
pathway, there must be some convergent point in immune signaling that is common to 
these diverse bacteria. Likewise, there must be a consistent signaling pathway engaged by 
both pulmonary and intestinal epithelial cells. For instance, to advance the infection 
process, the Gram-negative Salmonella Typhimurium, Shigella flexneri, E. coli, and P. 
aeruginosa all inject bacterial effectors through a type-III secretion system to influence 
eukaryotic host-pathways to make the cell more amenable to bacterial survival and 
replication. S. pneumoniae, on the other hand, is a Gram-positive bacterium without a 
conventional secretion system and that relies on bacterial attachment, self-lysis, or 
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currently unidentified efflux processes to influence eukaryotic cells during infection. 
While most of the bacteria on this list possess some ability to invade eukaryotic cells, 
Enteroaggregative Escherichia coli are thought to be obligatory extracellular pathogens 
(112). We have previously reported that the virulence factor SipA, which reduces the 
expression of the efflux transporter P-gp (which conveys analogous activity to MRP1 in 
the lung), also increases the activity of pro-inflammatory MRP2 (13). Although the 
actions of SipA and interacting proteins have been described in some detail (109, 113, 
114), no information on virulence factors coordinating the MRP2 activity in pulmonary 
infection have been elucidated. Identifying the factors by which S. pneumoniae initiates 
MRP2 enrichment on the apical surface of the plasma membrane and generates HXA3, 
will provide valuable information that could be critical in identifying a more general 
mechanism of this HXA3/MRP2 activation common to both the intestine and lung. Such 
an approach may also reveal potential therapeutic candidates, outside of HXA3 and 
MRP2, which researchers could target with small molecule inhibitors.  
This work is focused on two targets: 1) pneumolysin (PLY) and 2) bacterial-
derived hydrogen peroxide (H2O2). Pneumolysin is a member of the pore-forming 
cholesterol-dependent-cytolysins. During bacterial growth, pneumolysin is released from 
S. pneumoniae, though there is contention as to whether this is due to bacterial autolysis 
or a currently unidentified secretion system (67, 115). PLY monomers are released from 
bacteria and multimerize on the epithelium surface. Pores of up to 44 subunits form a pre-
pore ring at the base of the epithelial cilia and undergo a conformational change that 
excises a portion of the plasma membrane, forming the proper pore (116). Ciliary beating 
		
71	
slows, likely to allow for niche development, as the bacteria colonize the pulmonary 
system. Previous studies have indicated that PLY engages Toll-Like Receptor 4 (TLR4) 
and initializes NF-κB signaling to induce inflammation (117), though there is expectation 
that HXA3/MRP2 activation is largely independent of NF-κB signaling (3, 4, 118). In 
mice, PLY-deficient bacteria are much less virulent in during experimental infection. 
Serotype-2 S. pneumoniae without PLY showed reduced burden compared to wild-type 
bacteria during intranasal administration (119), less outgrowth during intratracheal 
infection (120), and less ability to invade through the epithelial barrier to cause 
bacteremia (120).  
Hydrogen peroxide is a by-product of ATP generation through the action of the 
pyruvate oxidase, SpxB (121). Because hydrogen peroxide has the potential to be 
detrimental to bacterial DNA, membrane, and proteins, most other bacterial species 
encode a gene to produce catalase, which neutralizes hydrogen peroxide into relatively 
harmless oxygen and water. S. pneumoniae, however, does not have a catalase gene, 
resulting in high concentrations of hydrogen peroxide during bacterial growth. In a 
process that is not completely understood, S. pneumoniae protects itself in other ways: it 
is suggested that DNA and iron (both sensitive to reaction with hydrogen peroxide) is 
sequestered to protect the organism (121). Bacterial glutathione peroxidase (PsaD) also 
assists in neutralizing oxidative pressure during growth (122).  SpxB also somehow 
confers protection from hydrogen peroxide buildup (121). Hydrogen peroxide is not just 
a waste product, however; in the ever-evolving bacterial arms race, S. pneumoniae likely 
developed survival mechanism in high oxidative stress to combat another nasal 
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commensal bacteria, Haemophilus influenzae. If H. influenzae and S. pneumoniae are 
grown together in the presence of one another, S. pneumoniae continues to multiply while 
H. influenzae is unable to cope with the oxidative stress (66). Pericone and colleagues 
observed that pyruvate oxidase mutations or exogenous catalase in growth media allowed 
both S. pneumoniae and H. influenzae to grow at equal rates, without an inhibition on the 
H. influenzae (66). In vivo experiments show that hydrogen peroxide is a necessary 
virulence factor during infection. Notably, spxB-mutant bacteria were less virulent, 
exhibited less lung growth, were not as adept as wild-type at invading the circulatory 
system, and did not cause as much inflammation (123) when compared to wild-type 
bacteria.  
Herein, we describe an intricate interplay between the pore-forming toxin PLY 
and bacterial-derived hydrogen peroxide. We reveal that eliminating either of these 
virulence factors prevents MRP2 enrichment on the apical surface of the epithelium and 
abolishes PMN transepithelial migration in vitro. The pneumolysin/H2O2 induction of 
HXA3/MRP2  appears to be calcium dependent, as mutation in either pneumolysin or 
neutralization of hydrogen peroxide with catalase resulted in elimination of intracellular 
calcium increases. Disrupting calcium signaling, likewise, eliminated PMN migration and 
MRP2 translocalization.  
These findings reveal that there are at least two bacterial factors modulating the 
epithelial HXA3/MRP2 axis and transepithelial PMN migration and that both of these 
influence intracellular calcium. Although there are many bacterial species that induce 
HXA3-dependent PMN transepithelial migration, only one virulence factor has been 
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identified as necessary: the Salmonella effector SipA (20). Additionally, ours is the first 
communication that reveals the necessity of calcium in MRP2 localization during PMN 
transepithelial migration. While our research identifies the necessity of PLY, it does not 
reveal the entire mechanism. Supplementing pneumolysin-deficient bacteria with the 
cytolysin perfringolysin O, instead of pneumolysin, results in similar PMN migration. 
The fact that two similar but distinct pore-forming toxins can mediate this activity may 
indicate a conserved mechanism of regulation for the HXA3/MRP2 proinflammatory 
response.  
 
3.2 Results 
PMN migration is dependent on Pneumolysin 
In Chapter II, we presented a model in which S. pneumoniae initiates HXA3 
synthesis and is subsequently vectorially effluxed from the cell via MRP2. While we 
demonstrated that MRP2 increases during infection, it remains to be determined what 
signal or signals from the S. pneumoniae promote the induction of MRP2 on the apical 
plasma membrane. The bacterial factors that we identify could be critical to elucidating a 
mechanism by which the epithelium activates the HXA3/MRP2 axis to assist in 
transepithelial PMN migration. To identify the signal or signals we took the following 
steps. 
We chose first to examine whether the pore-forming toxin, PLY, could impact 
epithelial-directed PMN transmigration. It is well documented that PLY mediates pro-
inflammatory signaling (124) and can mediate transendothelial diapedesis (125). 
		
74	
Moreover, it has been shown that sufficiently high concentrations of PLY can induce 
PMN migration (126). We therefore examined an in vitro model of transepithelial PMN 
migration that utilizes NCI-H292 cells that form a polarized monolayer on a semi-
permeable membrane construct (19). We then infected the apical surface with a serotype-
4, pneumolysin-producing strain of S. pneumoniae (TIGR4). Post-infection, the bacteria 
were washed away and freshly isolated human PMNs were placed in the basolateral 
chamber of the construct to simulate the basolateral-to-apical PMN migration through the 
epithelium. When infecting with a pneumolysin-deficient serotype-4 S. pneumoniae 
(ΔPLY) we saw a consistent 50% or greater reduction in PMN migration compared to 
wild-type bacteria (Figure 3.1A). To confirm that this is a pneumolysin-specific reduction 
we functionally complemented ΔPLY infections with purified pneumolysin.  
In functionally complementing ΔPLY bacteria, it was necessary to first identify 
the amount of pneumolysin released by the wild-type S. pneumoniae at 10 MOI during a 
one-hour infection time. To measure this, we collected supernatant from the apical 
surface of infected H292 cells, removed the bacteria, and examined the free pneumolysin 
via Western blot against a standard of purified pneumolysin (Figure 3.1B). Our data 
revealed two facts: first, it confirmed that ΔPLY mutant bacteria were unable to generate 
detectable levels of pneumolysin; second, the amount of pneumolysin detected in the 
infection supernatant during exposure to H292 cells was approximately 33ng/mL. 
Separate experiments examining the ability of PLY alone to induce PMN migration 
revealed that concentrations of PLY upward of 1 µg/mL could cause PMN transepithelial 
migration and this effect was lost at concentrations less than 300 ng/mL (Figure 3.1C). In 
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assessing apoptosis, it was observed that concentrations of purified PLY over 300 ng/mL 
caused apoptosis one hour post-infection in a dose-dependent manner (Figure 3.1D). 
Since the previous one-hour, MOI 10 wild-type S. pneumoniae infectious dose failed to 
induce measurable apoptosis (Figure 2.5), we next supplemented the ΔPLY mutant 
infection with 33ng/mL purified PLY and examined the resulting phenotype.  
During supplemented infections where ΔPLY bacteria were in solution with 
33ng/mL of the purified PLY, wild-type levels of transepithelial PMN migration were 
regenerated, thus indicating pneumolysin activity is necessary for PMN migration in our 
model (Figure 3.1A). There was no significant PMN migration in treatments with 
33ng/mL purified PLY by itself. Taken together, these results suggest that transepithelial 
migration is dependent on PLY to elicit PMN migration but 33ng/mL PLY is not 
sufficient by itself and likely requires at least one additional bacterial factor to stimulate a 
full, robust PMN transmigration at 10 MOI of S. pneumoniae.  
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Figure 3.1 Transepithelial PMN migration is pneumolysin dependent 
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(A) PMN migration with either mock-treatment (Buffer), infected with S. pneumoniae (S. 
pneumoniae), infected with the ΔPLY mutant strain (ΔPLY), treated with 33 ng/mL 
purified PLY alone (Purified PLY), or infected with the ΔPLY strain supplemented with 
purified PLY (ΔPLY+Purified PLY). PLY-deficient bacteria induced significantly less 
PMN migration than wild-type bacteria. PMN phenotype was regenerated with 
functionally complemented infection. (B) Western blot quantifying the amount of PLY 
produced by wild-type bacteria during infection. Standards were loaded 33 ng/mL or 300 
ng/mL purified PLY. Purified cell treatments were treated with 33 or 300 ng/mL of 
purified PLY and loaded into SDS-PAGE gel. Infected cells samples were infected with 
bacteria, supernatant was aspirated off, and then loaded into SDS-PAGE gel. Whole 
bacteria underwent bacterial cell lysis and loaded on to gel. Wild-type bacteria appear to 
release approximately 33 ng/mL of PLY. (C) PMN migration elicited after purified PLY 
treatment. As in (A), 33ng/mL was not a sufficient concentration to cause PMN 
migration alone. (D) Apoptosis as measured by Annexin AV staining. Concentrations of 
PLY greater than 300ng/mL caused increased apoptosis while wild-type 10 MOI 
infections with S. pneumoniae did not exhibit increases in apoptosis. Buffer indicates 
untreated cells. Staurosporine was used as a positive indicator of apoptosis. Statistics 
completed using Student T-test. NS refers to no significance. Shown are representative 
runs of at least 3 identical experiments.    
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Pore-forming Pneumolysin acts in conjunction with a signal from live bacteria 
Our first attempt at identifying the second PMN-transepithelial migration-
inducing signal involved heat-killed and UV-killed bacteria. We postulated that a general 
component of the bacteria, perhaps bacterial membrane, peptidyl-glycan, or lipoteichoic 
acid, might engage an immune receptor, together with PLY, to induce transepithelial 
PMN migration. For instance, heat-killed S. pneumoniae are still able to signal through 
TLR2, indicating some structural component engages even after the bacteria are dead 
(127). Similar to Figure 3.1A and C, monolayers of H292 were treated with suspensions 
of live bacteria or treated with killed bacteria together with purified PLY. Each treated 
monolayer was then subjected to the PMN transepithelial migration assay and assessed 
for PMN migration. In each case, whether the purified PLY was supplemented with S. 
pneumoniae killed with heat (Figure 3.2A) or UV (Figure 3.2B), the mixtures failed to 
induce PMN transepithelial migration. Likewise, wild-type S. pneumoniae that underwent 
heat-killing failed to induce any PMN transepithelial migration, even if supplemented 
with exogenous purified PLY (Figure 3.2C). Since none of the killed bacteria, mixed with 
purified PLY or not, were able to induce PMN migration we speculate that live bacteria 
were needed together with PLY to produce a full transepithelial PMN migration 
response.  
Conceptually, PLY could be interacting with the epithelial immune sensors in a 
variety of ways. One could be that the PLY ring structure excises plasma membrane upon 
pore formation and allows sodium, calcium, or even a soluble “second virulence factor” 
to enter the epithelial cell, influencing stress pathways and commencing an immune 
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reaction that culminates in HXA3/MRP2 activation. Another possible signaling 
mechanism is engagement of pneumolysin as a monomer or multimer at the plasma 
membrane surface through TLRs and other cell-surface receptors. Such receptors would 
signal upon being bound and subsequently induce the HXA3/MRP2 axis.  
To examine the possibility of whether pore formation was necessary or if the 
monomers/ring structure would suffice, we next sought to test mutations in PLY itself. 
We obtained a pore-forming mutant (“pre-pore”) that is unable to form functional pores 
but instead multimerizes on the epithelium without excising the eukaryotic membrane 
from the center of the ring structure. (128, 129). The pore-forming mutant was 
supplemented at the same concentration as the purified PLY (33 ng/mL) and applied to 
the H292 cells as per previous experiments. We found that the ΔPLY bacteria was no 
longer complemented upon infection with the pore-forming mutant, suggesting that 
complementation requires functional pores to induce PMN transepithelial migration 
(Figure 3.3). We therefore inferred that functional pores were necessary to engage HXA3 
production and undergo efflux during infection.  
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Figure 3.2 PLY complement requires live bacteria 
We examined the necessity of viable bacteria mixed with purified PLY to induce PMN 
migration. (A) Bacteria were grown to a given concentration and heat-killed by boiling 
for 30 mins. Killed bacteria were then washed and supplemented with purified PLY as in 
3.1A. (B) Bacteria were UV killed after growing to a given concentration. Bacteria were 
exposed to UV light for 30 mins and supplemented with purified PLY. (C) Wild-type 
bacteria were heat-killed by boiling for 30 mins and supplemented with purified PLY. In 
all cases, killed bacteria were unable to regenerate PMN migration with or without 
exogenous PLY added to the infection solution. CFU plating confirmed that greater than 
90% of bacteria were killed during boiling/UV exposure. Shown is a representative 
experiment. Experiments were conducted at least three times with similar results and 
statistics were conducted using a Students T-test. 
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Figure 3.3 Functional pores are necessary for PMN migration 
PMN migration conducted supplementing with either purified functional pneumolysin or 
a pre-pore lock that localizes to the plasma membrane but does not form functional pores. 
Pre-pore lock protein was isolated in a similar manned to purified PLY and applied at the 
same concentration. Pre-pore lock protein was unable to generate the PMN response by 
itself or mixed together with ΔPLY bacteria. Statistics were conducted using Student’s T-
test. Shown is one representative PMN transepithelial assay of at least 3 runs with similar 
results. 
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Pneumolysin acts in parallel or together with hydrogen peroxide to produce PMN 
migration 
With the conclusion that live bacteria and PLY were necessary to initiate HXA3 
production, it seemed reasonable to examine bacterial factors that are produced by 
metabolically active S. pneumoniae. Actively dividing S. pneumoniae use a number of 
sources of carbon, such as sugars and pyruvate to generate ATP. SpxB, the S. 
pneumoniae pyruvate oxidase, is responsible for production of acetyl-phosphate, which 
can then be converted to acetate or acetyl-CoA during respiration (130). During pyruvate 
metabolism, hydrogen peroxide is produced in large quantities due to the lack of a S. 
pneumoniae catalase. Studies have indicated that bacterial-derived hydrogen peroxide, 
together with PLY, can induce apoptosis in neurons and inhibit ciliary beating in 
epithelial cells (131, 132). Other Streptococcus species also use hydrogen peroxide as a 
virulence factor during infection (133, 134). We postulated that bacterial-derived 
hydrogen peroxide could induce PMN transepithelial migration together with PLY. In the 
first step of this examination, we tested the extent to which S. pneumoniae produced 
measurable levels of hydrogen peroxide in vitro. We used a colorimetric assay in which 
we aspirated media after exposure to S. pneumoniae for the normal infection time of our 
in vitro assays at 10 MOI. Under these conditions, S. pneumoniae produced 250 to 500 
µM hydrogen peroxide whether exposed to epithelial monolayers or incubated at 37 °C 
independent of epithelial exposure (Figure 3.4A). To neutralize hydrogen peroxide 
production, we treated S. pneumoniae resuspended in HBSS with 5 µg of catalase. It is 
possible to mutate the S. pneumoniae spxB, however, previous studies have shown that 
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this sensitizes the bacteria to killing with hydrogen peroxide. Additionally, genetic 
manipulation of spxB also reduces the amount of pneumolysin in experimental infection 
(115) – as such, we would not be able to examine whether reductions in PMN migration 
were due to hydrogen peroxide neutralization or pneumolysin reduction. The same 
studies showed that catalase treatment is effective at neutralizing S. pneumoniae-derived 
hydrogen peroxide without affecting the pneumolysin production during infection (115).  
Upon treatment with catalase, hydrogen peroxide was undetectable during S. 
pneumoniae growth and infection (Figure 3.4B). Catalase treatment also appeared to have 
no effect on the S. pneumoniae growth, as bacteria in the presence or absence of catalase 
grew at equal rates during one-hour incubations (Figure 3.4C). To examine whether 
hydrogen peroxide acted on the epithelium to produce PMN transmigration, we applied 
catalase treated or mock-treated bacteria to epithelial cells and conducted an in vitro 
PMN migration assay.  
After catalase treatment during infection steps, we observed a 90% reduction in 
PMN transepithelial migration as compared to mock-treated cells (Figure 3.5A). To 
ensure this effect was a S. pneumoniae specific occurrence, H292 cells were also exposed 
to catalase-treated Pseudomonas aeruginosa, a bacterium known to induce PMN 
migration in lung cells (18) but which possesses an endogenous catalase. We observed no 
difference in PMN migration between the P. aeruginosa-catalase-treated or mock-treated 
samples, leading us to conclude that catalase inhibition of the PMN migration appears to 
be specific to S. pneumoniae infection (Figure 3.5A). Pre-treating epithelial cells with 
catalase or including catalase during the post-infection PMN-migration step yielded no 
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such reduction, implying that the hydrogen peroxide is needed specifically during 
infection (Figure 3.5B). Due to the fact that catalase acts extracellularly and does not pass 
through the cell membranes, we favored the scenario that catalase was neutralizing S. 
pneumoniae derived hydrogen peroxide. Hydrogen peroxide is essential for S. 
pneumoniae-induced HXA3 production and, as such, the epithelium can no longer induce 
PMN transepithelial migration in conditions where the hydrogen peroxide has been 
neutralized.  
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Figure 3.4 Streptococcus pneumoniae produces measureable amounts of hydrogen 
peroxide 
(A) Hydrogen peroxide concentrations were measured in HBSS that contained bacteria 
for 1 hour (See Materials and Methods). Bacterial solutions were either incubated with 
bacteria alone (Streptococcus pneumoniae Alone) or incubated as during an in vitro 
infection with H292 cells (Streptococcus pneumoniae infected). There was no significant 
difference between the amount of hydrogen peroxide produced by the bacteria alone or 
the hydrogen peroxide in infected samples. (B) 5ug/mL of catalase neutralized hydrogen 
peroxide production in bacteria (without infection) during 1 hour growth in HBSS. (C) 
Catalase treatment had no effect on bacterial growth during the 1 hour process.  
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Figure 3.5 Catalase treatment inhibits PMN migration during S. pneumoniae 
infection 
Transepithelial PMN migration (A) in which bacteria were either mock-treated or 
incubated with catalase during the infection step. Catalase (yellow) effectively reduced 
PMN migration of Streptococcus pneumoniae infected cells as compared to mock-treated 
(black) but was unable to reduce PMN migration of the catalase-competent Pseudomonas 
aeruginosa. (B) Catalase treatment had no effect when epithelial cells were pre-treated 
with catalase or treated post-infection during transepithelial PMN migration. Catalase 
was only effective if exposed during infection with S. pneumoniae indicating catalase is 
acting in a S. pneumoniae-specific manner. Statistics performed using Student’s T-test. 
Shown is one representative PMN transepithelial assay of at least 3 runs with similar 
results. 
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Neither hydrogen peroxide nor PLY are sufficient to induce PMN transepithelial 
migration 
Earlier examination demonstrated that 33ng/mL of purified PLY, the equivalent 
amount of PLY produced by 10 MOI wild-type S. pneumoniae during a one-hour 
infection, was not sufficient to induce PMN migration in a transepithelial assay (Figure 
3.1). With the identification of hydrogen peroxide as an essential virulence factor, we 
sought to test whether the combination of hydrogen peroxide and PLY would be 
sufficient to drive HXA3 production in epithelial cells. We initially attempted to induce 
PMN migration by exposing H292 epithelium with a mixture of PLY and varying 
hydrogen peroxide conditions. PLY was either mixed with a single dose of 250 µM H2O2 
or a gradually increasing dose beginning at 0 µM and increasing to 250 µM (Figure 3.6). 
Under both conditions, PLY with the purified hydrogen peroxide was unable to induce 
PMN migration. To ensure that the window of efficacy was not being missed, the gradual 
hydrogen peroxide concentration was increased from 250 µM to 1 mM, to no effect 
(3.6C).  
The results of these experiments suggest a system in which hydrogen peroxide 
and pneumolysin work in conjunction with at least one other S. pneumoniae virulence 
factor to induce HXA3. It is not clear if this third signal acts independently of the 
hydrogen peroxide/PLY determinants or if it works in concert with these other two 
virulence factors. To examine whether this might be a soluble factor, we conditioned 
HBSS by allowing bacterial growth for one hour. We removed the S. pneumoniae, and 
then treated naïve cells with the bacterial-conditioned HBSS. H292 cells were unable to 
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mediate PMN transepithelial migration under such conditions (3.6D), indicating that the 
additional signals are not exclusively soluble factors.  
The physical attributes of cells tend to be preserved upon fixation with 
paraformaldehyde (PFA) and other fixative agents. We surmised that if the third signal 
required a physical interaction with the epithelium, in addition to hydrogen peroxide and 
PLY, fixed bacteria supplemented with H2O2 and PLY might induce transepithelial 
migration of PMNs. Therefore, ΔPLY bacteria were fixed with 4% PFA and (post-
fixation) supplemented with 300 µM hydrogen peroxide and 33ng/mL pneumolysin. 
These conditions failed to produce a significant PMN transepithelial migration response, 
indicating that the bacteria require some kind of active interaction together with hydrogen 
peroxide and pneumolysin (Figure 3.7) or a combination between soluble factors and 
physical interactions. Thus, we can conclude that to obtain maximal PMN migration, we 
need pneumolysin, hydrogen peroxide production, and at least one other, as of yet 
unidentified, signal.  
 
MRP2 localization is dependent on Pneumolysin and hydrogen peroxide 
 We previously showed in Chapter II that PMN transepithelial migration is 
dependent on the expression of the ABC-transporter MRP2 during infection (Figure 2.9). 
HXA3 efflux is mediated by MRP2 and in the previous section we demonstrated that 
transepithelial PMN migration is dependent on both pneumolysin and hydrogen peroxide. 
Thus, we next sought to probe how PLY and hydrogen peroxide impact the trafficking of 
MRP2 to the plasma membrane.  
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 Apical surface biotinylation allows us to track the proteins that localize 
exclusively to the apical portion of the plasma membrane. To examine the MRP2 plasma-
membrane enrichment during infection, we conducted apical biotinylations of wild-type 
infected, ΔPLY-infected, PLY-treated, and catalase-treated wild-type infected H292 cells. 
When exposed to the ΔPLY mutant, MRP2 was no longer enriched on the apical surface 
of H292 as compared to uninfected and wild-type infected cells (Figure 3.8A). Much like 
the PMN transepithelial migration data, purified PLY at 33ng/mL treatment was 
insufficient to induce MRP2 build up on the apical surface, demonstrating it is also 
necessary but not sufficient to cause MRP2 translocation. When complementing the 
ΔPLY mutant with purified PLY, we regenerated the MRP2 enrichment (Figure 3.8A). 
Similar to ΔPLY infections, when hydrogen peroxide was quenched via catalase, MRP2 
mobilization to the plasma membrane was eliminated (Figure 3.8B). MRP2 apical 
localization directly correlated with the results of the function in transepithelial PMN 
migration assay: i.e., MRP2 enrichment was observed during any condition in which 
PMN migration occurred. Any condition unable to induce PMN migration also exhibited 
no increase in MRP2 localization. 
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Figure 3.6 Purified PLY and hydrogen peroxide are both necessary but not 
sufficient alone or combined to induce PMN migration 
PMN migrations with PLY, hydrogen peroxide, and the combination of the two yielded 
no PMN migration. PLY was spiked at time 0 at the concentration of 33ng/mL in all PLY 
samples and hydrogen peroxide was either spiked at 250µM (A), increased from 0 up to 
250 µM every 10 minutes to replicate normal hydrogen peroxide production  (B), or 
increased from 0 to 1mM every 10 mins (C). (D) HBSS was conditioned with 
Streptococcus pneumoniae for 1 hour and then bacteria were removed. Conditioned 
media was insufficient to induce PMN migration by itself. Statistics performed using 
Student’s T-test. 
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Figure 3.7 Hydrogen peroxide and PLY treatment are not complemented with fixed 
bacteria 
Bacteria were fixed with 4% paraformaldehyde then combined with PLY pre- or post-
paraformaldehyde fixation, thinking that the PLY might need a bacterial membrane 
anchor to activate. PLY was also applied post-fixation and mixed with hydrogen peroxide 
(ΔPLY+H2O2+PLY) to examine if earlier heat-killing or UV irradiation might be 
disrupting structures that might be necessary for PMN migration. None of the stated 
conditions induced observable PMN migration. Statistics were conducted using Student’s 
T-test. Shown is one representative PMN transepithelial assay of at least 3 runs with 
similar results. 
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PMN migration and MRP2 apical enrichment are calcium dependent 
Given that MRP2 and PMN transepithelial migration appeared to be dependent on 
both virulence factors, we saw an opportunity to examine the possible synergistic nature 
of hydrogen peroxide and pneumolysin activity. We therefore examined what secondary 
messengers might be impacted by either hydrogen peroxide or pneumolysin and how 
such factors might work together to coordinate MRP2 apical fusion. In addition to many 
pro-inflammatory responses, it has been shown that pneumolysin and hydrogen peroxide 
induce increases of eukaryotic intracellular calcium that can signal damage or distress in 
the cell (135, 136). As it has been demonstrated that wild-type S. pneumoniae infection 
increases intracellular calcium (136), we began to examine how calcium signaling might 
impact HXA3-induced PMN transepithelial migration and MRP2 localization. First, we 
evaluated whether calcium increases in a detectable manner during our experimental 
process. Over a one-hour infection at 10 MOI, serotype TIGR-4 S. pneumoniae infection 
increased intracellular calcium concentrations in H292 cells by approximately 60% 
(Figure 3.9A).  
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Figure 3.8 MRP2 apical enrichment requires both hydrogen peroxide and PLY 
H292 cells were treated with (A) HBSS (Buffer), wild-type infected (Streptococcus 
pneumoniae), ΔPLY infected (ΔPLY), PLY-treated (Purified PLY, 33ng/mL), or ΔPLY 
infected with PLY (ΔPLY+Purified PLY, 33ng/mL). ΔPLY infections were not able to 
elicit the same MRP2 localization that wild-type bacteria were able to. Like PMN 
migration, PLY alone at 33ng/mL was unable to induce MRP2 translocation but 
complementing ΔPLY infections with purified PLY was able to regenerate the MRP2 
enrichment. (B) Catalase treatment also inhibited S. pneumoniae-induced MRP2 plasma 
membrane enrichment, showing that hydrogen peroxide is also necessary to induce wild-
type levels of MRP2 on the apical surface. GAPDH used as loading control.  
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While calcium influxes are usually observed in much shorter time-scales than the one-
hour infection, there is precedent in examining longer time-points of calcium increase 
(136). In uninfected cells, cells infected with pneumolysin-deficient bacteria, and cells 
infected in the presence of catalase, we saw no discernable increases in calcium. 
Hydrogen peroxide and pneumolysin treatment by itself at our experimental 
concentrations exhibited no increases either, leading us to conclude that there is likely a 
threshold event that must take place where calcium reaches specific concentration to 
initialize signaling.  
While calcium signaling is critical in many processes, we sought to examine 
whether epithelial-specific calcium signaling might be critical in PMN migration. We 
chose to eliminate apical calcium post-infection to investigate whether calcium influx in 
the epithelium during the post-infection time point was necessary to induce PMN 
migration. We compared this to cells incubated with media in which magnesium had 
been eliminated to elucidate whether changes in phenotype might be specific to divalent-
cations instead of solely calcium signaling. We could not eliminate calcium during  the 
infection as S. pneumoniae virulence relies on calcium (137). Similarly, eliminating 
calcium in the basolateral chamber might impact PMN signaling and activity during the 
PMN migration step. Under these conditions, we observed a large reduction in the PMN 
migration phenotype when calcium-free HBSS was used instead of conventional HBSS 
(Figure 3.9B). This did not appear the case in samples with reduced magnesium, 
indicating to a calcium-specific effect.  
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To more subtly assess the necessity of calcium on the system, we sought to 
examine whether the MRP2 apical increase was impacted by calcium decreases. When 
treated with the cell permeable intracellular calcium chelator, BAPTA, cells were no 
longer able to increase induce PMN transepithelial migration or MRP2 on the apical 
surface during infection (Figure 3.10). This outcome supported the hypothesis that 
calcium signaling impacted both MRP2 plasma membrane enrichment and HXA3 
production.  
Assuming that PLY only functions in inducing the HXA3/MRP2 axis through 
calcium mobilization, we assessed whether infection-independent induction of 
intracellular calcium could trigger PMN migration. We therefore investigated whether 
thapsigargin, a drug that normally causes cytosolic calcium buildup, could complement 
our ΔPLY infection. H292 cells were either mock treated or pre-treated with thapsigargin, 
washed, subjected to ΔPLY infection, and either underwent a intracellular calcium 
measurement or PMN transepithelial migration assay. We found that thapsigargin 
induced similar calcium increases during the infection time-frame (Figure 3.11A), but did 
not rescue the phenotype, nor did it cause transepithelial PMN migration. Not only did 
thapsigargin not rescue the PMN phenotype, but it also inhibited PMN migration in wild-
type infections (Figure 3.11B and C). Cells pretreated with thapsigargin, whether infected 
with ΔPLY or wild-type bacteria, were unable to mediate a PMN response. The 
thapsigargin observation seems to highlight that not only is calcium influx necessary, but 
specific types of calcium influx are important for pneumococcal-induce PMN 
transepithelial migration. 
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Figure 3.9 Intracellular calcium is a necessary component of transepithelial PMN 
migration 
(A) H292 cells were loaded with Fura-2-AM, infected or treated with the indicated 
conditions, then measured for one hour to detect intracellular calcium increases. S. 
pneumoniae induced a consistent increase in calcium while hydrogen peroxide, PLY, 
ΔPLY bacteria, and catalase treatment all were insufficient to increase the calcium. (B) 
PMN transmigration in the presence of absence of calcium and magnesium. H292 cells 
were exposed to wild-type bacterial infection for one hour and then allowed to undergo a 
PMN migration assay where the apical surface was deficient in either calcium or 
magnesium. To avoid situations in which the bacteria or PMNs might not be activated 
because of lack of the cation, the infections and basolateral chamber of the migration 
construct was kept whole with the normal calcium and magnesium concentrations. This 
assay revealed the need for calcium during PMN migration.  
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The requirement for proper calcium signaling is further underscored when we 
investigated the role of a second calcium mobilizer, ionomycin. Unlike thapsigargin, 
ionomycin induces calcium influx both from extracellular calcium as well as release from 
intracellular stores via pore formation (138). After treating cells with ionomycin and 
infecting with ΔPLY, the cells were subjected to a transepithelial PMN migration assay. 
We noted a recapitulation in the transepithelial PMN migration phenotype when ΔPLY 
bacteria infected cells that had been treated with ionomycin (3.12A). Additionally, 
ionomycin alone caused no PMN migration. The ionomycin-induced supplement was 
dose-dependent, and transepithelial PMN migration was lost when the ionomycin 
concentration was reduced from 1µM to 0.5µM.  
 On the balance of these observations, we concluded that there was a threshold of 
stress specifically placed on cells in order to elicit signals that induced calcium increases 
and led to MRP2-mediated PMN transepithelial migration. Furthermore, the calcium 
buildup appeared to be dependent on hydrogen peroxide and pneumolysin. Yet, the 
calcium mobilization was also specific; if calcium signaling was reduced via chelation or 
perturbed via thapsigargin, PMN transepithelial migration was inhibited. However, 
normal bacterial infection or ionomycin induction of calcium buildup was productive to 
facilitate the HXA3/MRP2 axis. One key similarity between ionomycin and pneumolysin 
is that both induce calcium across the plasma membrane by perturbing it by pore 
formation. Might other cytolysins send the same signal that PLY does? Perhaps the pore 
formation allowing for extracellular calcium signaling is a critical step in the infection to 
induce MRP2 localization and PMN migration.  
		
103	
To examine whether pore formation in general would produce a productive HXA3 
reaction, we supplemented our ΔPLY bacteria with perfringolysin O (PFO). 
Perfringolysin O is another cholesterol-dependent cytolysin produced by the Gram-
positive bacterium Clostridium perfringens and behaves in a similar manner to PLY 
(139). When we mixed ΔPLY bacteria with 33ng/mL of PFO and conducted a PMN 
migration, we observed a similar phenotype as when ΔPLY was supplemented with 
purified PLY (Figure 3.12B). This verified that there was likely a conserved mechanism 
influencing transepithelial PMN migration.  
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Figure 3.10 Intracellular calcium is necessary for PMN migration as well as MRP2 
localization 
Treatment of the H292 epithelium with the membrane permeable calcium chelator 
BAPTA resulted in reduction of intracellular calcium buildup and (A) reduced PMN 
migration after infection with wild-type S. pneumoniae. (B) Reduced the ability of MRP2 
to reach the apical surface during S. pneumoniae infection as observed during a 
biotinylation experiment. Cells were pretreated with BAPTA, washed, and then infected 
for one hour as normal. Shown is one run of at least three that showed similar results.  
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Figure 3.11 Intracellular calcium increases caused by thapsigargin reduces PMN 
migration  
 Thinking that artificially increasing intracellular calcium concentrations might 
recapitulate wild-type PMN migration during infection with the ΔPLY mutant, we first 
pretreated cells with thapsigargin. Thapsigargin increased calcium to similar levels as 
wild-type Streptococcus pneumoniae infection (A) but failed to complement ΔPLY 
infections during a PMN migration assay (B). Similarly, if cells pretreated with 
thapsigargin are infected with wild-type bacteria, the cells are no longer permissible to 
inducing PMN migration (C).  
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Figure 3.12 Calcium induction by Ionomycin complements ΔPLY infections 
(A) As expected with thapsigargin, pretreatment with the ionomycin increased PMN 
migration when infected with ΔPLY bacteria. This occurred in a dose-dependent manner 
and did not induce PMN migration by itself. (B) Likewise, replacement of PLY with 
another cholesterol-dependent-cytolysin, Perfringolysin O, at 33 ng/mL also 
complemented the ΔPLY infection during PMN migration assays. Statistics calculated 
using Student’s T-test. Shown is a representation transepithelial PMN migration of at 
least 3 runs exhibiting similar results.  
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3.3 Discussion 
We have previously demonstrated that there is a conserved innate immune 
reaction in both the intestinal and pulmonary systems that reacts to bacterial infection by 
initializing efflux of the PMN chemoattractant Hepoxilin A3. Active efflux of HXA3 is 
dependent on the ABC-transporter MRP2. There have been few reports about specific 
virulence factors and the upstream targets that assist in production and efflux of HXA3. 
Garnering this information is an important task because the HXA3/MRP2 axis appears to 
be conserved in both the intestinal and pulmonary organ systems. Additionally, there is 
evidence that HXA3 and MRP2 have a role in intestinal dysbiosis and autoimmune 
diseases – therefore identifying virulence factors and conserved epithelial response 
molecules underlying this pathway would shed light into how undesired PMN migration 
might be targeted or interrupted to disrupt aberrant inflammation. 
Herein, we demonstrate that PMN transepithelial migration to the site of an active 
S. pneumoniae infection is reliant on the virulence factors pneumolysin and hydrogen 
peroxide. PLY and hydrogen peroxide are both necessary but not sufficient either alone 
or in combination to induce PMN transepithelial migration in vitro. S. pneumoniae-
conditioned media was unable to induce PMN migration alone (Figure 3.6D), pointing to 
the necessity of either live S. pneumoniae or a physical host-pathogen interaction. 
Mixture with PFA-fixed S. pneumoniae, hydrogen peroxide, and PLY also yielded no 
PMN migration, indicating a need for either live bacteria or a combination of soluble and 
structural S. pneumoniae components.  
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 As stated, the MRP2/HXA3 axis is conserved in both the intestine and the lung, 
indicating the eukaryotic signaling processes detecting these virulence factors is likely 
also conserved, though it remains to be seen whether enteric bacterial virulence factors 
signal in a similar manner. To date, HXA3-dependent PMN transepithelial migration has 
been described in the context of infections including E. coli, Salmonella Typhimurium, 
Shigella, and Pseudomonas aeruginosa (4, 11, 12, 18). These bacteria do not produce 
pore-forming toxins or excessive amounts of hydrogen peroxide during their infection 
cycles, so it is exceedingly unlikely the same bacterial detectors would trigger PMN 
transepithelial migration. When assessing similarities between these bacteria, we find that 
there are few similarities to S. pneumoniae. In contrast to S. pneumoniae, these other 
bacteria are Gram-negative, encode type-III-secretion systems, and all harbor catalase, 
which will quench hydrogen peroxide. However, one particular trait common to all these 
bacterial pathogens is that they coopt host cell machinery to induce alterations in how 
membranes and vesicles are utilized in the cell. Pore-forming toxins need additional 
membrane fusions to repair S. pneumoniae-induced pores. Hydrogen peroxide can also 
mediate the Fenton reaction, requiring membrane repair. Salmonella, E. coli, and Shigella 
all hijack membrane components to allow for bacterial entry or niche development (via 
Shigella entry, Salmonella-containing-vacuole development, or E. coli pedestal 
formation). Although there are no readily identified membrane-manipulating virulence 
factors during Pseudomonas infection, it remains possible that the endosome/vesicle 
trafficking mechanisms might have perturbations leading to similar signaling. The Type-
III secretion apparatus, itself, may initialize immune function upon interaction with the 
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eukaryotic membrane. Observations that PLY-like cytolysins such as PFO can effectively 
complement pneumolysin-deficient S. pneumoniae reactions during PMN migration 
assays support the hypothesis that membrane perturbation may be linked to HXA3/MRP2 
activation (Figure 3.12B). Similarly, ionomycin, a molecule that increases intracellular 
calcium through pore formation, can complement ΔPLY infections.  
 Our hypotheses concerning membrane-trafficking manipulation go hand-in-hand 
with increases and decreases of the ABC-transporters on the plasma membrane surface. 
We have shown previously that increases of MRP2 on the apical surface of the lung 
epithelium is independent of new protein generation. Instead, it is likely that existing 
stores of the protein, held in endosomal vesicles, fuse with the plasma membrane and 
increase on the apical surface in this manner. There are current theories that plasma 
membrane repair during bacterial infection is paired with MRP2 increases through 
endosomal fusion at the plasma membrane. PLY-induced pores are excised as new 
membrane containing MRP2 is fused to the apical surface of the pulmonary epithelium, 
allowing for efficient membrane repair and initializing the pro-inflammatory response 
through HXA3 via MRP2.    
  One other common signaling molecule is intracellular calcium. It is known that a 
number of eukaryotic signaling events occur via calcium-mediated signaling, including 
production of IL-8 in Salmonella Typhimurium infections. Calcium, however, is a 
relatively common and ubiquitous secondary messenger and more specific signaling has 
yet to be elucidated with the MRP2/HXA3 axis. Nevertheless, our work identifies that 
both MRP2 translocation and corresponding PMN transepithelial migration are 
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dependent on pneumolysin, hydrogen peroxide, and specific calcium signaling. These 
factors likely link HXA3 generation and MRP2 activation through a conserved messenger 
system present in mucosal surface epithelial cells to induce PMN migration. It is likely 
that one common link is membrane perturbation or membrane repair and it is this 
particular activity that we may want to focus further work to elucidate the active players 
in MRP2 plasma membrane enrichment.   
   
3.4 Materials and Methods  
Cell culture 
The human cell line, NCI-H292 (H292) was cultured with RPMI (GIBCO 
#11875-093) supplemented with 10% FCS and subcultured using 0.05% Trypsin-EDTA 
(GIBCO #25300-054). Transmigration cells were prepared on 24-well inverted semi-
permeable membranes (Costar #3421) and grown to confluency. Cells for protein assays 
were grown to confluency on 6-well membranes.  
 
Bacteria 
Streptococcus pneumoniae serotype 4 (TIGR4) and Pneumolysin-deficient 
mutants (ΔPLY) were provided by Drs. John Leong and Andrew Camilli (Tufts School of 
Medicine). Bacteria were streaked overnight on 5% sheep-blood Tryptic Soy Agar 
(Northeast Laboratory Services #p-1100) and grown at 37°C, 5% CO2 for 14-20 hours. 
On the day of infection, bacteria were resuspended with Todd-Hewitt-Yeast media and 
supplemented with oxyrase (#OB-0100, 5uL/mL culture). Cultures grew to ~5x108 
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CFU/mL, as confirmed post-infection by CFU counting 18-24 hours later. ΔPLY 
complement with purified cytolysin, such as PLY, provided by Dr. Rod Tweten through 
Dr. John Leong, was performed by adding given amount to dilute to a final concentration 
as reported. Purified PLY procedure previously published (128, 140). In vitro infections 
were diluted in Hanks Balanced Salt Solution (HBSS, GIBCO #14025-092). Hydrogen 
peroxide (Sigma Aldrich Cat# H1009-100mL) treatments and supplements were at 
indicated concentrations. Catalase treatments were conducted by initially diluting catalase 
(Sigma Aldrich Cat#C1345-10G) in HBSS+ at 5µg/mL. This solution was then diluted 
1:10 in the infection solution and applied to epithelial cells.  
 
Bacterial killing assay 
 Wild-type and ΔPLY Streptococcus pneumoniae were cultured as above and 
washed with HBSS+ once. While in clear eppendorf tubes, bacteria were either exposed 
to UV light for 30 mins, boiled for 30 mins, or resuspended in paraformaldehyde (4% in 
Phosphate Buffered Saline [PBS]) for 30 mins. Bacteria were then centrifuged and 
resuspended with HBSS+ together with indicated conditions. CFU counting confirmed 
that >90% of bacteria had been killed by comparing to unkilled counterparts.  
 
Transmigration 
Transmigrations were conducted as previously described (3) using H292 cells. 
H292s were infected apically with wild-type TIGR4 (~10 MOI) for 1 hour and washed. 
Human neutrophils were isolated from healthy donors using methods previously 
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published (13). Freshly isolated neutrophils were applied to the basolateral chamber of 
infected membranes and allowed to migrate. Neutrophil migration was quantified using a 
myeloperoxidase assay.  
 
Biotinylation 
H292 cells were grown on 6-well transmembranes to confluency, rinsed with 
HBSS, and infected with TIGR4 (~10 MOI) apically. Cells were washed and biotinylated 
as previously described (109, 110). Cells were lysed and passed through 26½ -gauge 
needles, spun, and applied to streptavidin beads (Thermo Fisher #20347) or saved in 
tricine sample buffer (recipe from Bio-rad 161-0739). Biotinylated-bead samples were 
incubated at 4°C overnight, washed, incubated at 40°C for 20 mins in tricine sample 
buffer, then run on 4-20% TGX protein gel. Proteins were transferred on to nitrocellulose 
membranes, blocked, and incubated with the indicated antibodies: MRP2 (ABCAM 
ab3373), GAPDH (EMDMilipore MAB374). HRP-conjugated secondary antibodies were 
used to visualize western blots. 
 
Calcium examination 
Thapsigargin (Sigma Aldrich Cat#T9033-1MG), Ionomycin (Sigma Aldrich 
Cat#IO634-1MG), and BAPTA (Molecular Probes Cat#B1205) were diluted in HBSS+ 
and applied to H292 cells after initial wash prior to infection. Thapsigargin working 
solution 10 µM, diluted in HBSS. Cells were exposed for up to one hour and washed 
before assay. Ionomycin working solution 1µM and 0.5µM, cells were exposed for up to 
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one hour and washed before assay. BAPTA working solution was 25µM, cells were 
exposed to HBSS-diluted BAPTA for 30 mins, washed, infected as normal (for PMN 
migration) or biotinylated (For biotinylation). Solutions were added to the apical surface 
(600 µL) as well as the basolateral surface (100 µL) for 1 hour and washed away for 
transmigration assays. Similar steps were conducted for biotinylation assays. 
 Intracellular calcium was measured by loading H292 cells with Fura-2-AM 
(Molecular Probes Cat#F1221) per manufacturers instructions. Cells were either pre-
infection treated, treated with bacterial solution, or treated with cytolysin/hydrogen 
peroxide. For time course H2O2 experiments, cells were removed from their initial wells 
in a 24-well plate and added to a separate well containing the given concentration of 
hydrogen peroxide in pre-warmed HBSS+. Samples run every 2.5 mins for 1-hour. 
Increases of calcium were calculated by examining the excitation of 340 vs. 380 nm and 
emission at 510nm by an H4synergy plate reader.  
 
Hydrogen peroxide measurement 
Hydrogen peroxide was measured using a colorimetric assay as previously described 
(141). Briefly: Solutions were mixed with 1mL, 2% Potassium Iodide; 1mL, 2M HCl and 
mixed thoroughly. To this, we added 0.5mL, 0.01% Toluidine Blue, followed by 2mL 
Sodium Acetate. Final solution was measured at 628nm and measured against a blank 
containing only HBSS. 
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Chapter IV: Discussion and importance 
  
4.1 Introduction 
The following section restates the general findings of the thesis and discusses 
some of the alternative theories that were tested during the completion of this work. In it 
and the following appendix, I will discuss similarities and contrasts between pulmonary 
and intestinal infections and attempt to infer universal mechanisms controlling HXA3-
dependent PMN transepithelial migration and MRP2 enrichment on the plasma 
membrane. I will also discuss certain caveats that need to be addressed to give a complete 
picture of the work presented. 
 
4.2 Restating the Thesis findings 
At the beginning of this thesis work, PMN infiltration was known to be HXA3 
dependent in Gram-negative infections with Salmonella serotype Typhimurium (4), 
Shigella (11), and Pseudomonas aeruginosa (18) at a variety of mucosal surfaces. 
Ongoing research completed during my first few years of experimentation expanded this 
list to E. coli (12) infection in the intestinal tract and, finally, Streptococcus pneumoniae 
in pulmonary infections (19). Although reported critical in bacterial pulmonary 
infections, it remained to be seen how HXA3 was exported to the site of infection and 
whether mediation of HXA3 efflux was similar to the intestinal trafficking. We sought to 
examine whether mechanisms comparable to that in the gut, mediated by ABC-
transporters, might be key to HXA3 efflux. We initiated these studies in a semi-biased 
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approach, examining a variety of ABC-transporters for increases on the apical surface of 
the epithelium during infection, a hallmark of an HXA3 efflux transporter. As detailed in 
the introduction, there have been few reports that have assessed expression and activity of 
ABC-transporters in the lung under normal, basal states, so our goal was to help 
illuminate some of these details throughout our studies.  
Another specific goal during this investigation was to probe the correlation 
between inflammation, especially ABC-transporter-mediated PMN transepithelial 
migration, and infiltration of S. pneumoniae in to the blood. Previous studies had 
demonstrated a distinct relationship between PMN transepithelial migration and the 
ability for S. pneumoniae to disseminate and it was our desire to hone in on the transition 
from pulmonary infection to bacteremia. The greater goal was to examine whether 
obstruction of HXA3 efflux by targeting transporters for inhibition could lessen PMN 
infiltration and reduce bacterial entry into the blood.  
 Our initial observation was that, similar to efflux of HXA3 in the gut, MRP2 
increases on the apical surface upon infection with S. pneumoniae, as measured by apical 
immunofluorescence and apical biotinylation (Figure 2.2). Other ABC-transporters either 
decreased (MRP1) or showed no change (MRP4, MRP5). Still, others, were undetectable 
by both methods and were determined to either not be expressed by our in vitro cell lines 
or were too low to be detectable and, therefore, disregarded for future experimentation. 
Both MRP4 and MRP5 have been implicated in pulmonary reactions (27), though it did 
not appear they took part in HXA3-mediated transepithelial PMN migration, as there 
were no increases in MRP4 or MRP5 expression or enrichment on the membrane.  
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During functional studies, MRP1 was shown to efflux an anti-inflammatory 
molecule or molecules that we have termed L-AMEND (Chapter II). Similar effects 
correlating MRP1 and protection from inflammation have been reported in the intestine 
(35) as well as pulmonary conditions such as COPD (47). Our work correlates MRP1 
activity with reduction of PMN infiltration during bacterial infection. Similar activities 
have been reported in the intestine where eukaryotic P-gp effluxes a PMN-inhibiting 
molecule AMEND (159). In contrast, MRP2 effluxes the pro-inflammatory HXA3 during 
infection.  
 The MRP2 increase on epithelial cells appears dependent on both presence of the 
cholesterol-dependent cytolysin, pneumolysin, and bacterial-derived hydrogen peroxide 
(Chapter III). Eliminating either of these virulence factors limits PMN migration during 
in vitro studies, though neither appear to be sufficient in generating the PMN migration 
phenotype by themselves. Additional communications have detailed that pneumolysin 
and hydrogen peroxide work together to promote neuronal apoptosis during meningitis 
(131). When measuring the number of apoptotic cells during infection, it was shown that 
S. pneumoniae does not appear to induce wide-scale apoptosis during one-hour in vitro 
assays. Schreiber et al. reported similar observations that neither S. pneumoniae nor P. 
aeruginosa caused epithelial apoptosis during infection – the majority of apoptotic cells 
observed during the experiments were leukocytes (142). There has been a report that 
hydrogen peroxide causes DNA damage leading to apoptosis, however this study 
reported no increases of apoptosis prior to a 7-hour time-point when infecting with 200-
400 MOI, well above our in vitro experiments (123). Similarly, Schmeck et al. examined 
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caspase-6 associated apoptosis during infection with a pneumolysin-competent serotype 2 
pneumococcus and observed no increases prior to 8 hours of infection (97). Both PLY 
and hydrogen peroxide work together with live S. pneumoniae to induce an intracellular 
calcium increase that remains detectable 1 hour post-infection and which, if disrupted, 
completely abrogates PMN migration.  
 
4.3 MRP1 activity reduces PMN migration 
We have demonstrated in our in vitro model of PMN transepithelial migration that 
MRP1-mediated efflux of a substance we have termed “L-AMEND” reduces PMN 
transmigration. Likewise, we showed via biotinylation and immunofluorescence that 
MRP1 is not as abundant on the apical of in vitro tissue culture cells and ex vivo murine 
pulmonary tissue during infection with S. pneumoniae. Previous studies conducted by 
Schultz et al. have examined MRP1 deficiency in murine models of pneumococcal 
infection, resulting in increased survival when MRP1 is absent (49). As noted previously 
in Chapter 2, these studies used a slightly different infection model (intranasal infection, 
versus our infection method of intratracheal application) with serotype-3 bacteria. 
Nevertheless, the apparent dichotomy that the authors report Mrp1-deficiency reduces 
mortality and PMN infiltration actually might reveal a subtlety of the complexity of the 
system that we are studying. MRP1 reduction in cells has been suggested to be cytotoxic 
during pro-inflammatory reactions (35). PMNs, which express MRP1 on cellular 
membranes, might actually undergo early apoptosis, reducing numbers of infiltrating 
PMNs and resulting in the observations made in Schultz et al.  
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 Reductions in intestinal MRP1 during DSS-modeled inflammation have been 
shown to increase intestinal damage, indicating that that MRP1 may be protective during 
intestinal inflammatory events (36). Similarly, in COPD studies, lower MRP1 expression 
in lungs has correlated with increased inflammation (47). Both these conditions have a 
hallmark of significant infiltration of PMNs, a similar phenotype observed when we 
reduce MRP1 expression in our experimental models of pneumococcal disease. These 
observations all indicate a possible anti-inflammatory activity conferred by MRP1 that 
seems reduce PMN infiltration and inflammation. 
The reduction of MRP1 closely resembles a reduction in P-gp in the intestine as 
observed by our lab (159)(34). In this work, P-gp effluxes an anti-inflammatory 
endocannabinoid that reduces PMN migration in stable, uninfected states. P-gp is 
undetectable in NCI-H292 cells and our observations concerning MRP1 in pulmonary 
tissue mirrors the activity of P-gp in the intestine; therefore, it seems reasonable to 
hypothesize that MRP1 might occupy the same or a similar role in the lung to maintain 
homeostasis and resolve inflammation. Although there is indication that P-gp expression 
is increased due to the presence of the microbiota, there is no such study that indicates 
MRP1 needs similar priming by bacteria.  
 
4.4 Addressing MRP1 localization and reduction 
Classically, MRP1 is thought to be basolaterally located while MRP2 is apical. As 
mentioned in Chapter 1, there are conflicting reports in the literature about where each 
transporter localizes in the lung in uninfected, basal states and very little information as 
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to how these transporters are regulated during inflammation. While our in vitro 
immunofluorescence and biotinylation data specifically looks at the apical surface, our in 
vivo immunofluorescence does not distinguish between the two; meaning that some 
pulmonary MRP1 may localize to the basolateral surface. Regardless, the 
immunofluorescence signal reduces during infection in mouse tissue, which is consistent 
to observations made in vitro. Conceptually, whether MRP1 is also on the basolateral 
portion of the epithelium does not adversely impact our findings that it acts as an 
immunosuppressant mediator.  
MRP1 reduction mirrors reduction of P-gp in the intestine during Salmonella 
infection (34, 143). This has been shown to be a caspase-3 mediated event where 
intracellular portions of P-gp are cleaved at a -DXXD- motif, degrading the protein and 
reducing its effective concentration through a mediator known as “P53 apoptosis Effector 
Related to PMP-22” (PERP) (113). Although there is no information regarding caspase-
mediated cleavage of MRP1 in the current literature, there are 2 prospective sites: DXXD 
motifs at amino acid sequences 1081 and 1417 (DTVDS and DKLDH). It is possible that 
caspases are activated during Streptococcus pneumoniae infection and reduce MRP1 
through cleavage events, thus eliminating concentrations of L-AMEND and increasing 
the potency of proinflammatory modulators that attract PMNs from the basolateral 
surface.   
 
 
4.5 Isolating and validating HXA3   
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This thesis makes the supposition that there is interplay between MRP1, which 
effluxes anti-inflammatory molecules reducing PMN infiltration, and MRP2, which 
effluxes pro-inflammatory lipids, namely HXA3. When examining the activity of 
substances effluxed by MRP2, we have used a previously described method of isolating 
lipids that has been shown to enrich for HXA3 using a C-18 column followed by a 
functional assay, demonstrating the ability of these lipids to induce PMN migration on 
naïve epithelial cells (4, 11, 12).  
Present day, one of the most effective techniques to quantify HXA3 is by Mass 
Spectrometry. Current commercially available HXA3 actually contains a great deal of the 
degradation product of HXA3, which is biologically inactive in our assays. This has left 
very few options for identifying HXA3. To ensure our bioactive lipids were enriched for 
hepoxilin, we relied instead on the chemical composition of HXA3 to assist in 
identification.  HXA3 is an eicosanoid that contains an epoxide ring (Figure 4.1A). HXA3 
is the only known lipid PMN chemoattractant with an epoxide ring. Soluble epoxide 
hydrolases are chemicals that break these three-member rings, degrading them to alcohol 
groups and hydrocarbons. The epoxide hydrolase renders HXA3 unable to function, 
thereby giving us a measureable output for a functional HXA3 assay. When we applied 
epoxide hydrolase to our isolated lipids (Figure 2.9A) and then tested the ability of those 
lipids to induce transepithelial PMN migration, we observed a sharp decline in the 
number of PMNs that traversed the epithelial layer compared to mock-treated lipids 
(Figure 4.1B). This demonstrated that the C-18 isolation method provides for significant 
enrichment of an epoxide-containing lipid that induces PMN migration, namely HXA3.  
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There was one other possible epoxide-containing lipid that we identified through 
a literature search: Thromboxane A2 (TXA2). TXA2 is a ubiquitous lipid reagent that 
activates platelets. While there is no evidence that TxA2 acts as a PMN chemoattractant, 
we treated the apical surfaces of polarized H292 cells with TxA2 inhibitors and conducted 
a PMN migration assay to ensure the epoxide hydrolase effect wasn’t TxA2 dependent. 
No differences were observed between wild-type S. pneumoniae infection or those cells 
treated with TxA2 inhibitors (Figure 4.1C), therefore we concluded that HXA3 is most 
likely the source of lipid PMN chemotactic activity. 
  
4.6 Global MRP2 protein remains static while MRP2 protein localization at the 
epithelial surface increases 
We have reported that total MRP2 protein from cell lysis does not change during 
infection as measured by western blot (Figure 2.1) and that it is protein enrichment of 
MRP2 on the plasma membrane that increases in the context of S. pneumoniae infection 
(Figure 2.2). Total cellular content of MRP2 protein in intestinal epithelial cells during 
Salmonella infection, in contrast, seems to increase (13), although this increase occurs 
absent of transcriptional increase. MRP2 is able to undergo a number of different post-
translational modifications, which may increase protein stability and, thereby, increase 
protein availability. One explanation as to how MRP2 increases on the apical surface 
absent of new protein synthesis is that during infection MRP2 is directed from a different 
subcellular location to the plasma membrane. Due to MRP2 identity as an integral 
membrane protein, it is likely that MRP2 sequestered from the plasma membrane is, 
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instead, stored in endosomal vesicles and awaits a directed signal to fuse to the plasma 
membrane, effectively increasing its concentration on the cell surface. Enrichment of this 
kind can be mediated by a family of Ezrin-Radixin-Moesin (ERM) proteins. ERM 
proteins are chaperones that assist directed transport of integral membrane proteins 
contained in endosomal vesicles. Previous reports have identified that both ezrin and 
radixin assist in directing MRP2 to the apical surface of the plasma membrane in in vitro 
intestinal cells (144). Furthermore, Agbor et al. demonstrated that Ezrin assists MRP2 in 
apical enrichment during Salmonella enterica Typhimurium infection (109). It is our 
expectation, therefore, that lung epithelial cells selectively increase MRP2 on the apical 
surface through a coordinated endosomal fusion activity directed by one of the ERM 
family proteins, most likely Ezrin.  
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Figure 4.1 Isolating and enriching HXA3 from infected H292 cells 
(A) Structure of Hepoxilin A3.  HXA3 is the only known lipid that contains an epoxide 
ring and confers PMN chemoattractant activity. (B) Classically, HXA3 has been 
identified using LC/MS/MS together with functional assays that induce PMN migration. 
A functional assay using lipids isolated from S. pneumoniae infection, however, identifies 
the majority of PMN chemoattractant as a proinflammatory lipid with an epoxide ring. 
(C) Although HXA3 is currently the only lipid chemoattractant that fits that description, 
there is another epoxide-containing lipid, Thromboxane A2 that is a candidate although 
there is no information supposing that TXA2 acts as a PMN chemoattractant. When we 
treat our infection milieu with a TXA2 inhibitor, we see no inhibition, making it all the 
more likely that the efflux payload of MRP2 during infection is HXA3.  
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4.7 Reasoning for Probenecid usage and dosing strategy 
In studying MRP2 inhibition during experimental S. pneumoniae infection, we 
settled on a single intratracheal dose of conventional Probenecid pre- and post-infection 
after optimization indicated that this was the method most efficacious in limiting PMN 
infiltration. Although MRP2 knockout mice are commercially available, genetic 
manipulation of the ABC transporters has caused compensatory increases in other 
transporters (145). In addition, a global knockout of MRP2 in mice could have trans 
effects from liver or immune function that is avoided by local application of Probenecid. 
Although Probenecid could possibly affect other MRPs, it has been shown to have 
high affinity for MRP2 but not P-gp. It is also possible that higher concentrations of 
Probenecid inhibit other anionic transport systems, such as MRP5 and MRP4 (29, 81, 92) 
(5mM for MRP5; 500 µM MRP4, 50mg/kg in vivo), but our in vitro concentration of 100 
µM is well short of these concentrations. Additionally, in vivo application of 1 mg/kg of 
Probenecid intratracheally is unlikely to inhibit MRP4 or MRP5. MRP1 exhibits a 
decrease in plasma membrane protein content during infection when we observe an 
increase in PMN migration, so it is unlikely a further reduction during Probenecid 
treatment in MRP1 activity would reduce PMN migration. 
 
4.8 Intratracheal application of S. pneumoniae is most effective in assaying lung-to-
blood transmission and development of bacteremia 
 Intratracheal application of S. pneumoniae ensured that we assessed the possible 
bacterial lung-to-blood transition that may have been absent during intranasal infection. 
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Although intratracheal delivery may have caused more physical irritation than intranasal 
application of the bacteria, there were no discernable differences between Probenecid-
treated and PBS-treated uninfected mice, meaning any irritation caused by intratracheal 
application of the bacteria seemed to be minimal and normalized between the two 
treatments. When measuring different cytokines and leukocyte infiltrations to the lung, 
we saw no discernable differences between Probenecid and PBS-treated mice, besides 
PMN infiltration to the lumen of the lung (Figures 2.5, 2.6, and 2.7).  
 It seems prudent to emphasize that Probenecid inhibition of MRP2 is not meant to 
reduce PMNs or PMN activity, per se. The goal of MRP2 inhibition via Probenecid was 
to reduce the transepithelial migration of PMNs from the basolateral-to-apical surface of 
the epithelial cells. The expectation was that there would be fewer PMNs infiltrating the 
lumen but all other signals, such as IL-8, TNF, IL-1β, and other leukocytes would remain 
consistent between PBS- and Probenecid-treated mice. In addition, the signals governing 
PMN extravasation and traffic to the basolateral portion of the epithelium remain intact. 
With the fact that Probenecid is limiting only the physical exit of the PMNs from the 
basolateral portion of the epithelium, it is remarkable that we observe such a reduction in 
bacteremia and increase in survival. These observations, however, highlight the 
importance of PMN infiltration kinetics. 
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4.9 Purified PLY forms functional pores that successfully supplement ΔPLY 
mutations 
 We received the purified pneumolysin, pre-pore lock mutant protein, and 
perfringolysin from the lab of Dr. Rod Tweten (129). The purification methods have 
previously been described (128, 140). Briefly, the cytolysins are produced in E. coli, 
isolated, and resuspended in storage buffer to freeze at -80 °C. We identified that PLY is 
necessary but not sufficient in Chapter III (Figure 3.1) with use of a pneumolysin-
deficient mutant (ΔPLY) and functional complement with the purified pneumolysin. One 
caveat to this study is whether the protein, purified from E. coli and supplemented during 
infection, forms pores and mimics the wild-type protein. All controls indicated that when 
supplementing the ΔPLY mutant with amounts of purified PLY equal to those previously 
measured during wild-type infections (33 ng/mL, Figure 3.2), the PMN phenotype is 
restored. The pre-pore mutant protein, purified in the same manner and supplemented at 
the same concentration, did not rescue the PMN migration phenotype, indicating that any 
component of the sample preparation or buffer was unlikely contributing to the induction 
of transepithelial PMN migration (Figure 3.3). Data indicating the pre-pore lock protein 
does not supplement ΔPLY infections also would indicate that the unmutated cytolysins 
form functional pores able to replicate the wild-type activity.  
It has previously been described that PLY can interact with TLR4 (117), and a 
lesser extent TLR2 (146), to induce immune function. We, therefore, tested different 
neutralizing antibodies to TLR2 and TLR4 during a PMN transepithelial migration. There 
were no differences between isotype controls and the specific antibody-treated samples, 
		
131	
leading us to conclude that the HXA3-dependent PMN transepithelial migration did not 
require TLR2 or 4 (Figure 4.2). This is not to say that TLR2 or TLR4 are completely 
dispensable for PMN migration: this particular assay specifically investigates the 
necessity of TLR2 and 4 in the context of HXA3. Additionally, there is likely some non-
specific activity conferred by PLY, as it was observed that administration of ΔPLY-
mutant bacteria together with another of the cholesterol-dependent-cytolysin, 
perfringolysin O, recapitulated the PMN migration phenotype (Figure 3.12B). 
 Our initial studies investigating wild-type S. pneumoniae infection for one-hour at 
10 MOI revealed no increase in apoptosis (Figure 2.12B and 3.1D). We observed, 
however, that increasing concentrations of purified PLY were effectively inducing 
apoptosis after one hour of treatment at concentrations of 300 ng/mL and higher. 
Although some previous studies have reported epithelial apoptosis and cell death (97, 
123) during S. pneumoniae infection, these studies have infected in vitro cells at 200-400 
MOI for extended periods of time, up to 16 hours. In addition, Schreiber and colleagues 
noted that the majority of apoptosis in the lung during S. pneumoniae infection actually 
appeared to be dying macrophages and that the epithelium remained largely viable, albeit 
injured (142). In context of examining transepithelial PMN migration, it is not entirely 
understood how epithelial apoptosis might affect the number of traveling leukocytes, 
which was why we focused on PLY concentrations that did not independently induce 
apoptosis (Figure 3.1C and D).  
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4.10 Catalase neutralizes bacterial hydrogen peroxide production 
Catalase treatment of S. pneumoniae-containing media resulted in neutralization 
of hydrogen peroxide. Catalase had no effect on epithelial cells prior-to or post-infection, 
indicating that treatment only affects the transepithelial PMN migration when catalase is 
mixed with S. pneumoniae during infection (Figure 3.5B). Additionally, hydrogen 
peroxide is required during S. pneumoniae induced MRP2 enrichment on the plasma 
membrane (Figure 3.8B). Catalase had no effect on bacterial growth (Figure 3.4C) and 
has been shown to have no effect on pneumolysin production (115), thus the effects of 
catalase should be hydrogen peroxide specific. This indicates that bacterial hydrogen 
peroxide is a factor that contributes to MRP2-mediated transepithelial PMN migration. 
The main virulence factor contributing to hydrogen peroxide production is the S. 
pneumoniae pyruvate oxidase gene spxB. spxB mutant bacteria are known to be deficient 
in virulence (123), more sensitive to oxidative stress (121), and produce less pneumolysin 
that its wild-type counterparts (115). For this reason, we chose to eliminate hydrogen 
peroxide stress using catalase instead of genetic manipulation. In contrast to spxB 
manipulation of S. pneumoniae, catalase treatment does not influence pneumolysin 
production (115). Additionally, a number of different studies have used catalase to 
eliminate hydrogen peroxide stress and none have reported off-target side-effects (66, 
115, 123, 132, 147, 148).  
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Figure 4.2 Neither TLR2 nor TLR4 blocking antibodies reduce PMN transepithelial 
migration during S. pneumoniae infection 
H292 cells were pre-treated with TLR2 and TLR4 neutralizing antibodies and then 
underwent a PMN transmigration assay. Neither TLR2 nor TLR4 blocking seemed 
sufficient to reduce PMN migration.  
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4.11 Live bacteria are needed to induce Transepithelial PMN migration 
During infection, S. pneumoniae are undergoing active growth processes, 
meaning production of both the pneumolysin and hydrogen peroxide is dynamic, not 
static. Original inspection on the necessity of PLY demonstrated that a single, one-time 
addition of purified PLY allowed for complement of the ΔPLY bacterial infection (Figure 
3.1A). Due to the fact that a single, spiked addition of 33 ng/mL of PLY was sufficient to 
complement the ΔPLY infection, subsequent experiments examining a range of hydrogen 
peroxide concentration used the single-dose application of 33 ng/mL PLY. PLY mixed 
with a single-dose of 250µM H2O2 (Figure 3.6), time-course increase to 250µM H2O2 
(Figure 3.6), time-course to increase to 1mM H2O2 (Figure 3.6), and time-course increase 
to 300µM H2O2, together with PFA-fixed bacteria (Figure 3.7) all yielded no observable 
increases in PMN transepithelial migration. It was our conclusion that PLY, hydrogen 
peroxide, and a third signal from live bacteria were needed to fully induce HXA3-
mediated transepithelial PMN migration.  
There remains a second possibility: there may be a need for a combination of 
PLY, hydrogen peroxide, at least one other soluble factor from live bacteria, and at least 
one physical interaction between S. pneumoniae and host. Presumably if only soluble 
factors (PLY, hydrogen peroxide, and the aforementioned unidentified soluble factor) 
were needed, media conditioned with S. pneumoniae for one hour would induce PMN 
migration during treatment with naïve H292 cells during a PMN migration assay (Figure 
3.6 D). A similar argument can be made with the mixture of PLY, hydrogen peroxide, 
and PFA-fixed bacteria: if there were a necessary fourth soluble signal, that would 
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explain why we observe no PMN migration with the PLY, hydrogen peroxide, and PFA-
fixed bacteria. 
  
4.12 Speculating how intracellular calcium increases interact with PLY/hydrogen 
peroxide-specific induction of PMN migration 
While we know eukaryotic intracellular calcium increases during S. pneumoniae 
infection, it remains to be seen how calcium specifically affects the MRP2/HXA3 axis. 
We reasoned that calmodulin might influence downstream signaling due to the calcium 
increases. This did not appear the case, however, as calmodulin inhibition by the drug W-
13 had no effect on migration (Figure 4.3). Likewise, we postulated that PLY and 
hydrogen peroxide might induce calcium-dependent signaling in the unfolded-protein 
response that occurs in some cellular stress responses. Inhibition of the stress response 
with salubrinal showed no impact on the ability of epithelial cells to mediate PMN 
migration (Figure 4.3B), indicating that calcium signaling appears independent of these 
two processes. There remain other possibilities:  
1) Calcium signaling assists in activation of PKC and PLA2, which is important 
in HXA3 formation 
2) Calcium and potassium influx influences cell-stress processes 
3) Calcium influx specifically from the extra-cellular space induces annexins 
which, in turn, activate MRP2 fusion and HXA3 production 
The Annexin possibility is particularly intriguing. Annexins are most widely known for 
their association with apoptosis; however, at earlier stages of cellular insult, Annexins 1, 
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2, and 6 are helpful inflammatory/cell survival signals (149). Annexin A1 and A2, in fact, 
have been theorized to assist in cell membrane repair during cholesterol-dependent 
cytolysin injury, of which PLY is a member. Annexin mediated pore repair is calcium 
dependent. Our data reflecting that calcium chelation and thapsigargin both interfere with 
PMN migration (Figures 3.10A and 3.11C) is provocatively reminiscent of observations 
communicating similar calcium dependency on membrane repair (150) .  
 There is a model of pore repair theorized in Andrews et al. in which the authors 
propose endosomal fusion of membrane to cytolysin-pore-damaged plasma membrane 
and microvesicle shedding as a method of cellular repair (151). While microvesicle 
shedding likely occurs (152), it still remains unclear whether endosomal fusion occurs. 
Endosomal fusion pore repair would be a rather favorable explanation for MRP2 
increases on the plasma membrane. The process would begin with S. pneumoniae 
induced cell injury through PLY pore formation, calcium increase, and Annexin A2 
activation. Annexin A2 would assist in guiding endosomes to the plasma membrane and 
MRP2-containing vesicles would fuse to the plasma membrane, excising the pore-
containing membrane as a microvesicle. MRP2, now on the plasma membrane, would 
efflux HXA3 from the apical surface and create the chemotactic gradient to draw PMNs 
through the epithelium to the site of infection. However, this does not account for the 
requirement of hydrogen peroxide. Hydrogen peroxide can also increase calcium influx 
(135) by itself and Annexin A2 is also known to be activated by hydrogen peroxide stress 
(153). The initiation of arachidonic acid release and MRP2 apical increase may only need 
to reach a certain threshold of calcium signaling by PLY, hydrogen peroxide, and the 
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third signal to fully activate the specific AnnexinA2. We will further discuss these 
possibilities in the Appendix.  
 
4.13 Future focus 
The most glaring piece of the S. pneumoniae infection puzzle is the missing 
identity of the third virulence factor necessary to induce PMN migration. Media 
conditioned with S. pneumoniae (that is, that contain PLY, hydrogen peroxide, and 
additional soluble virulence factors) does not elicit PMN migration (Figure 3.6D). This 
observation, together with data that a mixture of purified hydrogen peroxide, PLY, and 
UV-killed bacteria did not induce PMN migration, indicates that the virulence factor(s) 
might be a surface exposed protein that is only visible to the eukaryotic cell during the 
bacteria life-cycle. Asmat et al. suggested that engagement of the eukaryotic pIgR via 
virulence factor Choline-binding Protein A (CbpA, PspC) might induce a similar calcium 
increase (136) as that which was observed during our calcium assays. During intracellular 
measurement assays, we observed a reduction in calcium signaling during ΔCbpA 
infections as compared to wild-type S. pneumoniae. ΔCbpA bacteria also produced 
almost twice as much hydrogen peroxide, with equal numbers of bacteria, creating a 
situation in which hydrogen peroxide concentrations in the ΔCbpA mutant bacteria might 
introduce confounding factors if we examined it more in the context of transepithelial 
PMN migration (Figure 4.4A and B). We cannot discount the possibility that CbpA or 
another, related, virulence factor might be engaging the pIgR and signaling in a similar 
manner.  
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Another common virulence factor that might be influencing the epithelium is the 
biofilm that forms during bacterial niche development. PLY has been shown to assist in 
formation (154) of the biofilm. We tested whether reductions in PLY or hydrogen 
peroxide might disrupt biofilm formation during experimental infection steps. Whether 
incubating with the PLY-deficient ΔPLY mutant or disrupting hydrogen peroxide with 
catalase, we saw slightly less biofilm formation as compared to wild-type cells (Figure 
4.4C). It remains to be seen, however, how the biofilm might influence calcium influx in 
the epithelium.  
One last theory is that the epithelial cells, themselves have a catalase that 
neutralizes the hydrogen peroxide production from the bacteria and to combat this, the 
bacteria have an unidentified virulence factor that neutralizes the catalase. Eukaryotic 
catalase activity might also explain why in co-cultures with Haemophilus influenzae, it is 
Streptococcus and not Haemophilus that wins out during bacterial growth. As there is no 
such identified virulence factor, this is complete conjecture but would explain why viable 
S. pneumoniae are necessary for induction of PMN migration during purified PLY 
supplement experiments. Without the catalase-inhibitor, PLY may act but hydrogen 
peroxide that we add exogenously is neutralized and cannot signal, thus curtailing 
HXA3/MRP2 signaling. 
On the eukaryotic front, we have demonstrated that MRP2 is critical for the robust 
pulmonary HXA3-dependent transepithelial PMN migration that occurs during S. 
pneumoniae infection. It has recently been communicated that the pulmonary HXA3 
process also relies on the intracellular activity of PLA2 (17). It remains to be seen how 
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PLA2 activity might modulate MRP2 localization to the plasma membrane of the lung 
epithelium.  
 Although it was posed in other areas of this thesis, one particular topic of interest 
is the identity of the efflux payload(s) mediated by MRP1. We have demonstrated that 
MRP1 is associated with anti-inflammatory activity (through L-AMEND, Figure 2.11) 
during basal state, but the components of L-AMEND remain unidentified. PMN 
activation/inhibition is classically accomplished by extracellular engagement of G-
Protein Coupled Receptors (GPCRs). It has recently been reported that P-gp mediates 
efflux of endocannabinoids in the intestine to reduce and resolve inflammatory events 
through GPCR signaling, but it remains to be seen whether MRP1 might interact with 
inflammatory cells in a similar manner (159). Identification of L-AMEND can be 
completed through combinations of mass spectrometry, analytical chemistry, functional 
PMN migration assays, and GPCR activity assays.  
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Figure 4.3 PMN transepithelial migration during S. pneumoniae infection does not 
rely on ER stress signaling or calmodulin 
When examining how calcium might be signaling to induce PMN migration, we sought 
to determine if calmodulin might be necessary. The calmodulin inhibitor W-13 was 
purchased and cells were treated for one hour pre-infection with W-13 then underwent 
infection and subsequent PMN migration. Calmodulin inhibition did not result in any 
reduction in PMN migration. Similarly, we utilized the ER stress inhibitor Salubrinal to 
inhibit the ER stress unfolded-protein signaling process and performed a PMN migration 
assay. This treatment did not impact PMN migration either, pointing to other possible 
calcium signaling being important during infection.  
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When comparing the epithelial response to bacteria in both the pulmonary and 
intestinal tract, one area of interest is the conserved nature of the HXA3/MRP2 axis. 
Previous reports have demonstrated a convergence in HXA3 production at PLA2 release 
of arachidonic acid, which occurs in both the pulmonary and intestinal tissue (11, 12, 16, 
17). At this juncture of HXA3 synthesis, from arachidonic release to 12/15-Lipoxygenase 
activity and production of HXA3, the players are all the same in the pulmonary and 
intestine epithelium. Upstream, however, there are unique virulence factors that initiate 
PLA2. We have identified two possible candidates: hydrogen peroxide and PLY. It is 
already known PLY is able to activate PLA2 in endothelial cells (155) but no evidence 
exists for its induction in epithelial cells. In a more general sense, once a virulence factor 
is identified, identifying other virulence factors from other bacterial infections and 
comparing mechanisms of PLA2 activation would be very informative. 
Finally, there is a pertinent question about the convergence of MP2 translocation 
and 12/15 Lipoxygenase activation. In this study, we consistently observed MRP2 apical 
enrichment only in conditions where transepithelial PMN migration also occurred. There 
appears to be an obvious commonality between these two events that almost necessitates 
further investigation.  
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Figure 4.4 Possible third signals for S. pneumoniae PMN migration 
Hydrogen peroxide and PLY are insufficient to generate PMN migration by themselves at 
the concentrations that are associated with our 10 MOI infectious dose. (A) In seeking a 
third signal from S. pneumoniae, we chose to examine the protein CbpA which has been 
reported to be critical for intracellular calcium build-up through its association with the 
poly-Ig Receptor (pIgR). While CbpA-deficient mutants were unable to generate wild-
type amounts of intracellular calcium during infection, ΔCbpA bacteria also generated 
almost twice as much hydrogen peroxide as wild-type counter parts, leading to possibly 
confounding results. (B) Biofilm formation as measured in crystal violet stain after 
culture with the indicated bacteria. Both catalase and ΔPLY mutants exhibited slightly 
less biofilm formation as wild-type bacteria, though it was not statistically significant. 
This points to the possibility that CbpA and biofilm activity might be involved but must 
be examined in other ways to conclude whether they are critical for PMN migration.  
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4.14 Concluding remarks 
 While many questions still exist as to how the pulmonary epithelium fully 
coordinates PMN infiltration during S. pneumoniae infection, this work has clarified 
some crucial players and processes. At basal state, MRP1 remains high on the epithelial 
surface and effluxes an anti-inflammatory molecule to reduce the risk of non-specific 
PMN infiltration. This mirrors activity of the ABC-transporter P-gp in the intestinal tract. 
S. pneumoniae, upon infiltrating the lower respiratory system, comes in contact with the 
apical surface of the epithelium and initializes a proinflammatory state. S. pneumoniae 
releases PLY, hydrogen peroxide, and at least one additional unidentified but critical 
virulence factor. These virulence factors work together to activate the HXA3/MRP2 axis. 
Infection and interaction with the aforementioned virulence factors coincides with a 
reduction of MRP1, allowing for pro-inflammatory processes to begin. Arachidonic acid 
is released from the plasma membrane by PLA2 and converted to HXA3 by 12/15-
Lipoxygenase. HXA3 is transported to the infected apical surface and forms a 
chemoattractant gradient that draws PMNs from the basolateral surface of the epithelium. 
HXA3 production and release occurs in a similar manner during bacterial infection of the 
intestine, leading to the expectation that HXA3 efflux is consistent across other mucosal 
surfaces with a common instigating event, such as plasma membrane disruption or 
calcium signaling. One other critical step during S. pneumoniae-elicited transepithelial 
PMN migration is that intracellular calcium increases through the combined activity of 
hydrogen peroxide, pneumolysin, and the unidentified third virulence factor. Intracellular 
calcium increase sets in motion MRP2 increase on the plasma membrane. MRP2 effluxes 
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HXA3 to the apical lumen to draw PMNs from the basolateral to apical surface of the 
epithelium. In the case of Streptococcus pneumoniae infection, there is a tradeoff by 
allowing PMNs to infiltrate: while PMNs are necessary to control the bacterial infection, 
they also open paracellular junctions to allow for bacteria to invade the blood stream. By 
limiting the transepithelial travel of PMNs, we can effectively reduce the incidence of 
experimental bacteremia, which might have implications for other inflammatory and 
autoimmune diseases.    
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Figure 4.3 Revised model of Pulmonary HXA3-directed PMN transepithelial 
migration by MRP2 
As detailed by this work, Streptococcus pneumoniae infect the lower respiratory system 
and produce a number of virulence factors including pneumolysin and hydrogen 
peroxide. During this inflammatory, MRP1 reduces on the apical surface of the 
epithelium. Intracellular calcium increases in a manner dependent on pneumolysin, 
hydrogen peroxide, and a third, unidentified, virulence factor. This initializes production 
of HXA3 and increase of MRP2 on the apical surface of the plasma membrane, likely 
through endosomal fusion. MRP2 effluxes the pro-inflammatory HXA3 to draw PMNs to 
the site of infection, an action that both promotes clearance of the bacteria but also 
correlates with development of bacteria during experimental infection.   
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Appendix A 
Possible mechanism by which Annexin A2 modulates MRP2 localization via 
hydrogen peroxide and pneumolysin 
 
 As stated in the future works section of this thesis, Annexin A2 is an interesting 
molecule to examine during pneumococcal infection of epithelial cells. We observe 
increases in Annexin A2 in wild-type infections examining whole-cell lysate probed by 
western blot but not during catalase treatment or pneumolysin-deficient contexts. We also 
observe a perturbation in the normal localization of Annexin A2 examining 
immunofluorescence whereas ΔPLY infections and catalase treatments cause infections 
to reflect an uninfected morphology (Figure A.1). Annexin A2 is currently thought to be 
important in, among other things, microvesicle shedding and membrane repair (150-152). 
It is already known that hydrogen peroxide and pneumolysin activate Annexin A2 in 
some contexts and that Annexin A2 requires calcium increases to function. It remains to 
be seen, however, how specifically Annexin A2 is involved in HXA3 production and 
MRP2 localization.  
Our current theory is that hydrogen peroxide, together with pneumolysin, allow 
for external calcium influx and mobilization of Annexin A2. Separately, cPLA2 is 
activated by dissociation with a small subunit protein S100A10 (p11) (156). This p11 
forms a heterotetramer with 2 p11 monomers and 2 separate Annexin A2 monomers in a 
calcium dependent manner and mediates microvesicle shedding of plasma membrane 
damaged by pneumolysin. We also speculate that Annexin A2 might be involved in 
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plasma membrane fusion of MRP2-containing vesicles, increasing the MRP2 at the site 
of infection, the apical surface. Annexin A2 is also a protein with links to Salmonella 
infection (157) and pedestal formation during E. coli infection (158), making it a 
tantalizing target to examine as a common thread between intestinal and pulmonary 
induction of local MRP2 increases.  
 These current theories take into account hydrogen peroxide and pneumolysin 
activity but do not explain the necessity of a third virulence factor that assists in inducing 
PMN transmigration and MRP2 apical enrichment. Annexin signaling is very sensitive to 
specific local calcium concentrations and might require a certain threshold of calcium to 
be reached before being activated. Might that calcium threshold be crossed only when the 
third signal is incorporated with the other two? This theory also doesn’t take into account 
the Salmonella virulence factor SipA, for if SipA is able to cause PMN migration by 
itself, how might it signal through Annexin A2?  
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Figure A.1 Annexin A2 signaling differs between wild-type S. pneumoniae and 
ΔPLY and catalase-treated bacteria 
(A) H292 cells were cultured on semipermeable membranes to confluency and treated 
with either HBSS (Buffer), infected with S. pneumoniae, infected with ΔPLY bacteria, or 
infected with S. pneumoniae together with catalase. Annexin A2 immunofluorescence 
staining appears very clear and throughout the cytoplasm in uninfected cells. Catalase 
treatment and ΔPLY mutants exhibit similar staining post-infection. Wild-type S. 
pneumoniae, however, exhibits a more diffuse staining which may reflect a progression 
towards the membrane. (B) Western blot of whole cell lysate probing for Annexin A2. 
Annexin A2 appears to increase with wild-type bacterial infection whereas the uninfected 
sample (Buffer), ΔPLY mutant infection, and catalase treatment seem to stay lower.  
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Additional Materials and Methods 
All PMN transepithelial migrations, calcium measurements, immunofluorescence, and 
western blots performed as described in Chapters II (pages 62-66) and III.  
Specific reagents: 
Epoxide hydrolase purchased from Cayman Chemical (Cat#10011669). Lipid solution 
was resuspended and incubated with 100 µg/mL for 1 hour as previously described (108).  
Thromboxane A2 inhibitor (Cox-1 inhibitor) Indomethacin was purchased from Santa 
Cruz Biotechnology (Cat#sc-200503) and used at 200 nM for 1 hour, washed away, and 
PMN migration conducted as previously described.  
TLR4 (invivogen cat#PAb-hTLR4) and TLR2 (ebioscience cat# TL2.1) blocking 
antibody were incubated with H292 cells (10 µg/mL) prior to infection and PMN 
migration conducted as previously described.  
Calmodulin inhibitor (Sigma Aldrich SML0717-5MG) was diluted at 300 µM for 1 hour 
and PMN migration conducted as previously described.  
ER Stress inhibitor Salubrinal (Sigma Aldrich Cat#SML0951-5MG) was used to treat 
H292 cells at 50 µM for one hour and PMN migration conducted as described. 
Biofilm assay conducted as follows: Bacteria were cultured to the desired OD, placed in a 
microtiter 96-well plate and incubated for 1 hour. Post-incubation, bacteria were removed 
and plates were washed, stained with 1% crystal violet for 30 mins, washed, and 
solubilized with 30% glacial acetic acid. Absorbance was read at 595nm. Samples were 
run in triplicate. 
Annexin A2 antibody purchased from Abcam (Cat#41803).  
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